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A. ABSTRACT 
BBK32, a fibronectin (Fn)-binding protein of Borrelia (B.) burgdorferi sensu lato (s.l.) 
which is encoded by the bbk32 gene located on the 36kb linear plasmid (lp36) of isolate 
B31, is playing an important role in serological diagnosis of Lyme borreliosis. Firstly, we 
were interested in the genomic localization of bbk32 regarding different B. burgdorferi s.l. 
species as well as between strains of the same species. Southern blot analyses based on 23 
strains of the species B. burgdorferi sensu stricto (s.s.), B. afzelii, B. garinii and B. 
spielmanii revealed that position of bbk32 is rather variable between the species but also 
within a given species. bbk32 could be located on different linear plasmids (lp), mainly on 
lp23kb, lp24kb, lp25kb, lp31kb and lp36kb. The meaning of this finding remains unclear so 
far. Secondly, a mumber of thirteen chimeric polypeptides representing different parts of 
the N-terminal regions of BBK32 proteins of both B. burgdorferi s.s. isolate B31 and B. 
garinii isolate PHei were generated. Fn-binding capabilities of those generated 
polypeptides were evaluated either by Western-ligand blot-based binding assay or by 
enzyme-linked immunosorbent assay (ELISA)-based binding assay. Results showed that 
BBK32 from PHei possesses a higher Fn-binding capability than that from B31. 
Furthermore, the higher Fn-binding capacity is associated with four amino acids (Lysine131, 
Lysine145, Threonine147 and Isoleucine155) in the 32-amino acid-long segment (from 
position 131 to 162). Moreover, both gelatin and collagen could partially inhibit the 
binding of BBK32 to Fn. This suggests that BBK32 might also bind to the collagen-binding 
domain of Fn (repeat I6-9 and II1, 2) and partially to its N-terminal fibrin-binding domain 
(repeat I1-5). Though the meaning of the different Fn-binding capacities remains unclear so 
far, such studies may provide us with markers to define the different pathogenic potentials 
of various Borrelia species and strains. Thirdly, eight recombinantly prepared BBK32 
homologues (either as partial or as whole) were tested in a line assay to evaluate their 
contribution for serologic diagnosis of Lyme borreliosis. Though BBK32 homologues 
could react with sera from Lyme borreliosis patients, compared with other 
Borrelia-antigens established in the Max von Pettenkofer Institute, these BBK32 
homologues could not improve the sensitivity and specificity of the class-specific IgG or 
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IgM antibody tests. Nevertheless, this study underlines the fact that the heterogeneity of 
Lyme disease Borrelia species must be taken into consideration in the microbiological 
diagnosis of Lyme borreliosis in European patients. 
 
 
Zusammenfassung 
BBK32 ist ein Fibronectin (Fn)-bindendes Protein des Bakteriums Borrelia (B.) 
burgdorferi sensu lato (s.l.). BBK32 wird durch das bbk32-Gen, das im 36 kb linearen 
Plasmid (lp36) des Isolates B31 liegt, kodiert und spielt eine wichtige Rolle in 
serologischen Verfahren für den Nachweis von Lyme Borreliosis. Als erstes waren wir an 
der Lokalisierung von bbk32-Gen in verschiedenen B. burgdorferi s.l. Spezies sowie in 
verschiedenen Stämmen derselben Spezi interessiert. Southern-Blot-Analysen von 23 
Stämmen der Spezies B. burgdorferi sensu stricto (s.s.), B. afzelii, B. garinii und B. 
spielmanii zeigten unterschiedliche Lokalisation des bbk32-Gens sowohl in den 
verschiedenen Spezies, als auch in verschiedenen Stämmen derselben Spezi. Das 
bbk32-Gen konnte in verschiedenen linearen Plasmiden (lp), hauptsächlich in lp23kb, 
lp24kb, lp25kb, lp31kb und lp36kb, lokalisiert werden. Die Relevanz dieser 
unterschiedlichen Lokalisierung ist nicht klar. Zweitens, es wurden 30 chimäre 
Polypeptid-Sequenzen aus unterschiedlichen Bereichen der N-terminalen Region des 
BBK32-Proteins von B. burgdorferi s.s. Isolat B31 und B. garinii Isolat PHei generiert. Die 
Fn-Bindungsfähigkeit dieser hergestellten Polypeptide wurde entweder mittels eines 
Western-Ligand Blot-basiertes Bindungstestes oder eines Enzymgekoppelter 
Immunadsorptionstest (ELISA)-basiertes Bindungstestes evaluiert. Die Ergebnisse zeigten, 
dass BBK32 aus PHei ein höheres Fn-Bindungspotenzial als BBK32-Polypetide aus B31 
aufweist. Außerdem ist die höhere Fn-Bindungsfähigkeit mit dem Vorhandensein der vier 
Aminosäuren: Lysin131, Lysin145, Threonin147 und Isoleucin155 im 32-Aminosäuren 
langen Segment (von Aminosäure-Position 131 bis 162) assoziiert. Darüber hinaus konnten 
sowohl Kollagen als auch Gelatine die Bindungsfähigkeit von BBK32 an Fn teilweise 
inhibieren. Dies deutet darauf hin, dass BBK32 vielleicht auch an 
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Kollagen-Bindungsdomäne in Fn (Motive I6-9 and II1, 2) und teilweise an der N-terminalen 
Fibrin-Bindungsdomäne (Motive I1-5) binden könnte. Obwohl die Bedeutung der 
unterschiedlichen Bindungsfähigkeit an Fibronectin noch unklar ist, diese Studie könnte 
Marker zur Identifizierung diverser Borrelia-Spezies und –Stämme mit unterschiedlichem 
Pathogenitätspotenzial liefern. Drittens, acht rekombinant hergestellte homologe 
BBK32-Proteine (gesamte oder nur Teil-Sequenzen des Proteins) wurden für ihre mögliche 
Verwendung für serologische Verfahren zum Nachweis von Lyme Borreliosis in einem 
Linientest geprüft. Obwohl BBK32-Homologe mit Seren aus Patienten mit Lyme 
Borreliosis reagierten, konnten diese, gegenüber anderen im Max von Pettenkofer-Institut 
etablierten Borrelien-Antigene, zu keiner Erhöhung der Sensitivität und Spezifität des 
klassenspezifischen Nachweises von IgG oder IgM im Antikörper-Test führen. 
Nichtsdestoweniger unterstreicht diese Arbeit die Tatsache, dass die Heterogenität der 
Borrelien-Spezies bei der mikrobiologischen Diagnose von Lyme Borreliosis in Betracht 
gezogen werden muss. 
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B. INTRODUCTION 
Lyme borreliosis (or Lyme disease) is a multisystem disease involving many organs, 
mainly the skin, nervous system, joints and heart (Steere, 1989; Pfister et al., 1994; Stanek 
and Strle, 2003). As the most prevalent and widespread vector-borne infectious disease in 
the northern hemisphere, Lyme disease is caused by Borrelia (B.) burgdorferi sensu lato 
initially detected in the American tick vector Ixodes (I.) scapularis (Burgdorfer et al., 1982). 
B. burgdorferi s.l. is transmitted to humans by the bite of infected hard ticks belonging to I. 
ricinus / I. persulcatus species complex (Johnson, 1996).  
1. Discovery of Lyme borreliosis 
The first record of a condition associated with Lyme borreliosis dates back to 1883 in 
Breslau, Germany, where a physician named Alfred Buchwald described a degenerative 
skin disorder now known as acrodermatitis chronica atrophicans (ACA). Then, throughout 
the early twentieth century, many of the symptoms and signs that constitute Lyme disease 
were already described independently of each other. Finally, Lyme disease gets its name 
from a small coastal town in Connecticut called Lyme. In 1975, a woman brought to the 
attention of Yale researchers an unusual cluster of more than 51 cases of mostly pediatric 
arthritis. In 1977, Dr. Allen Steere and Yale colleagues identified and named the 51 clusters 
“Lyme arthritis." In 1979, the name was changed to "Lyme disease," when Steere and 
colleague Dr. Steven Malawista discovered additional symptoms linked to the disease such 
as neurological problems and severe fatigue. In 1982, the cause of the disease was 
discovered by Dr. Willy Burgdorfer. Dr. Burgdorfer published a paper on the infectious 
agent of Lyme disease and earned the right to have his name placed on the Lyme disease 
spirochete now known as Borrelia burgdorferi (Burgdorfer et al., 1982). Two years later, 
the isolation of spirochetes from the CSF of a patient with Bannwarth’s syndrome further 
confirmed that spirochetes are the pathogenic agents of Lyme disease (Pfister et al., 1984). 
In China, Lyme disease cases were first found in Hailin County, Heilongjiang Province in 
1986 (Ai et al., 1988). In 1987, B. burgdorferi strains were first isolated from I. persulcatus 
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collected from the same area (Zhang et al., 1989). Some important history events in the 
discovery of Lyme disease are listed in Table B-1. 
Table B-1. Timeline of important events in the discovery of Lyme disease 
Year Event 
1883 The first record of a condition of Lyme disease was described by Alfred Buchwald. He 
described it as a degenerative skin disorder now known as acrodermatitis chronica 
atrophicans (ACA).  
1909 Arvid Afzelius presented his research about an expanding, ring like skin lesion, erythema 
migrans (EM), associated with what would become known as Lyme Disease. 
1921  Arvid Afzelius published his work and speculated that the rash came from the bite of an 
Ixodes ricinus tick and connected the disease with joint problems. 
1922  The disease was found to be associated with neurological problems. 
1930  The disease was found to also cause psychiatric symptoms. 
1934  Patients with benign lymphocytoma also had either EM or ACA. Arthritic symptoms were 
reported in connection with the disease. 
1970  Rudolph Scrimenti reported an EM known with certainty to have been acquired in the United 
States.  
1975  Allen C. Steere, Yale, investigated a group of rashes and swollen joints in Lyme, Connecticut. 
Scrimenti published about his treatment of the rash with penicillin. 
1976  A clustering of cases of the disease was reported in Naval Medical Hospital in Connecticut. 
1977  Steere et al. misdiagnosed Lyme disease as juvenile rheumatoid arthritis and named this 
condition ‘Lyme arthritis’.  
1982  The etiological agent of the disease, B. burgdorferi, was discovered by Dr. Willy Burgdorfer. 
1984 Pfister HW and his colleagues isolated spirochetes from the CSF of a patient with 
Bannwarth’s syndrome. 
1986 Lyme disease cases were found in Hailin County, Heilongjiang Province in China.  
2. Epidemiology 
2.1 Frequency of Lyme borreliosis 
Although Lyme borreliosis is the most commonly reported tick-borne disease in the 
northern hemisphere including North America and Eurasia, few data are available about its 
actual frequency in several regions. Its prevalence is estimated to range between 20 and 
100 cases per 100.000 inhabitants in the USA and about 100 to 130 cases per 100.000 in 
Europe (Huppertz et al., 1999; Hengge et al., 2003). In China, investigations suggested that 
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around 5.0% of the surveyed residents from 30 provinces were antibody positive for B. 
burgdorferi. Typical cases of Lyme disease were diagnosed in 11 provinces, especially in 
the northeast forest areas. And more than 130 isolates of B. burgdorferi were recovered 
from patients, ticks or animals in 19 provinces (Cui, 2004; Zhang et al., 1997). However, 
reported cases of Lyme disease are thought to represent only seventh of the actual number 
of people with the disease all over the world (Campbell et al., 1998). Lyme borreliosis 
occurs with similar gender preference with the exception of ACA, which is more frequent 
in women. Early neuroborreliosis cases showed a bimodal age distribution with a lower 
frequency in adults whereas ACA occurs primarily in older patients (Wilske, 2005). 
High-risk groups include people who work or spend time outdoors such as farmers, 
foresters, umberjacks, scientific researchers, hikers, trail workers, runners, and vacationers. 
2.2 Causative agents 
The agents of Lyme borreliosis are borrelia, bacteria of the spirochaete family, which are 
grouped in the B. burgdorferi s.l. species complex and further divided into 14 different 
genomic species. Only four out of them are assured to cause human disease: B. burgdorferi 
s.s. (the only human pathogenic species present in the USA), B. afzelii, B. garinii and the 
only recently described species B. spielmanii. B. spielmanii so far has only be described in 
rare cases with erythema migrans. Although the DNA of B. valaisiana, B. lusitaniae, and B. 
bissettii has already been detected in samples of human origin, or the spirochetes were 
isolated from the patients with symptoms of Lyme borreliosis, whether these species to be 
pathogenic for humans is still unclear (Fingerle et al. 2008; Richter et al. 2006; Stanek et 
al., 2003; Wilske et al., 2007a, Picken et al., 1996; Zhang et al., 1997; Wan et al., 2002; 
Zeng et al., 2002; Masuzawa et al., 2001; Chu et al., 2008; Rudenko et al., 2009). B. 
burgdorferi s.l. have a length of 20-30µm and a width of only 0.2-0.3µm. Hence, most 
spirochetes cannot be viewed using conventional light microscopy. Dark-field microscopy 
should be used to view spirochetes (Fig.B-1).  
 
 
 
INTRODUCTION 
 7
Due to the diversity of the outer membrane protein OspA, the three main pathogenic 
species (B. burgdorferi s.s. B. afzelii and B. garinii) comprise at least 7 different OspA 
serotypes in Europe. OspA serotype 1 corresponds to the species B. burgdorferi s.s., OspA 
serotype 2 to B. afzelii, and the OspA serotypes 3-7 to the B. garinii complex (Wilske et al., 
1993) (Table B-2). Distribution of the different OspA serotypes and thus also of the species 
is very different in isolates from skin biopsy specimens, CSF or ticks. Skin isolates, 
especially those from ACA, show a predominance of B. afzelii, whereas CSF and tick 
isolates mainly belong to B. garinii. However, regarding the latter species, the various 
specimen types differ in the prevalence of their B. garinii-associated OspA serotypes (Table 
B-2). Though initially lyme arthritis was exclusively linked to B. burgdorferi s.s., 
OspA-type specific PCR has revealed that Borreliae detected in synovial fluid specimens of 
patients suffering from Lyme arthritis are heterogeneous (Table B-2) (Eiffert et al., 1998; 
Vasiliu et al., 1998). The most frequent genomic groups in Europe, B. afzelii and B. garinii 
occur across the continent and the islands, whereas the third frequent group B. burgdorferi 
s.s. has only rarely been isolated in eastern Europe (Hubalek et al., 1997). The 
heterogeneity of OspA has important implications for vaccine development in Europe as 
well as for diagnostics (e.g. ospA PCR). Quite recently, the pathogenic potential of the new 
species B. spielmanii was confirmed by the finding of the corresponding pathogen in 
patients with EM from the Netherlands, Slovenia, and Germany (Wang et al., 1999a; 
Fig. B-1. Giemsa stained Borrelia burgdorferi (with kind permission of Prof. Wilske). 
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Fingerle et al., 2008).  
Table B-2. Distribution of B. burgdorferi s.l. species and OspA types in European isolates from 
ticks, cerebrospinal fluid (CSF), skin and synovial fluid specimens (Wilske et al., 2007a). 
 
Species 
OspA  
type 
Ticks (%) 
(n = 90) 
CSF (%) 
(n = 43) 
Skin (%) 
(n = 68) a 
Synovial fluid (%) 
(n = 20) b 
B. burgdorferi s.s. 1 20 19 6 33 
B. afzelii 2 9 12 84 29 
B. garinii c 3–7 71 69 10 38 
a. Source of skin specimens known in 46 patients (30 cases of EM, with 1, 26, 1 and 2 cases infected 
with OspA types 1, 2, 4 and 6, respectively; 16 cases with ACA, with one and 15 cases infected with 
OspA types 1 and 2, respectively. 
b. B. burgdorferi s.l. speciation from synovial fluid samples is based on ospA PCR results. Culture 
isolates from this tissue were too few to estimate species distribution. 
c. Tick and CSF isolates differ in the percentages of OspA types 4 and 6. OspA type 6 was found in 53% 
of tick isolates, but in only 23% of CSF isolates. In contrast, OspA type 4 was found in 28% of CSF 
isolates, but was not isolated from ticks. 
2.3 Vectors and reservoirs 
B. burgdorferi s.l. complex are transmitted by hard ticks (Ixodes spp.): In the U.S. they are 
transmitted by I. scapularis (Eastern regions) and I. pacificus (Western regions), in Europe 
and western Asia by I. ricinus (Fig. B-2) and in Asia by I. persulcatus (Stanek et al., 2003). 
I. persulcatus played a leading role in the transmission of B. burgdorferi to human beings 
in the northern part China, I. granuatus and Haemaphysalis bispinosa might serve as 
principle vector of the agents in the southern region (Wan, 2002; Ai et al., 1990). The 
larvae and nymphs feed primarily on small rodents whereas adult ticks feed on a variety of 
larger animals. In Europe small mammals such as mice and voles provide reservoirs for B. 
afzelii, B. burgdorferi s.s, and B. garinii serotype 4, and birds are reservoirs for B. garinii 
and B. valaisiana (Gern et al., 1998; Huegli et al., 2002). Rodents and birds also form the 
reservoir for B. burgdorferi s.s. in North America (Piesman, 2002). Genus apodemus and 
Clethrionomys might serve as a major reservoir for B. burgdorferi s.l. in China. Some 
cattle, sheep, dogs and rats from forest areas possessed a high antibody titer for B. 
burgdorferi s.s. (B31) (Wan, 2002), however, whether these animals also serve as 
reservoirs for B. burgdorferi s.l. is unclear so far. Birds might also play an important role as 
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both hosts of ticks and vectors of B. burgdorferi s.l. (Olsen et al., 1995; Kipp et al., 2006; 
Ishiguro et al., 2000, 2005). In unfed ticks B. burgdorferi s.l. lives in the midgut. During 
the blood meal on humans or other hosts, Borreliae have to migrate to the salivary glands 
wherefrom they are transmitted via saliva to the host. In most European regions the average 
infection rates for I. ricinus range from 10 - 20 % (Gern et al., 1993). However, there are 
marked differences in the infection rates of the various developmental stages of the ticks: A 
study carried out in Southern Germany revealed that of over 3.000 ticks about 20% of the 
adults, 10% of the nymphs and 1% of the larvae were infected (Fingerle et al., 1994; 
Wilske et al., 1987). The Borreliae are thus mostly acquired by feeding on infected 
reservoir hosts during the developmental cycle and only rarely transmitted transovarially. 
The life cycle of the hard tick Ixodes spp and the transmission of Borrelia to human beings 
are illustrated in Fig. B-3.  
 
Fig. B-2. Adult Ixodes ricinus. Left, male; Right, female. (from Dr. Boesebeck). 
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3. Symptoms 
Lyme disease comprises three stages: early localized, early disseminated, and late-stage 
manifestations (Steere et al., 2004). The natural course of untreated B. burgdorferi 
infections varies considerably, and the various clinical manifestations can occur alone or in 
various combinations (Steere et al., 2004; Oschmann et al., 1999). In most cases, the 
infection is self-limiting, but in rare cases, B. burgdorferi might persist and chronic disease 
manifestations could develop. The early and late stages are usually separated by an 
asymptomatic interval. 
Fig. B-3. Life cycle of the hard tick Ixodes ricinus and transmission of the organism 
that causes Lyme borreliosis. (With kind permission of Dr. Boesebeck, HMR, Germany).  
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3.1 Stage I (days through weeks after the tick bite)  
The early stage of Lyme disease is often characterized by a distinctive, expanding red rash 
that usually develops at the site of the tick bite. This rash, known as erythema migrans 
(EM), is the hallmark and best clinical indicator of Lyme disease (Fig. B-4). The center of 
the expanding annular lesion often fades to produces a bull’s-eye appearance. However, the 
extension, color intensity and duration of EM vary considerably. In addition, general 
accompanying symptoms such as low fever, myalgia, headache and, rarely, meningism 
may occur.  
3.2 Stage II (weeks through months after the tick bite) 
In some patients, hematogenous dissemination of the pathogen to other organs and tissues 
may occur (stage II). Patients sometimes feel quite ill and may present with fatigue, 
headache, fever, malaise, arthralgia and myalagia, symptoms that may last for weeks. 
Multiple erythemata migrantia (Fig. B-5) as sign for dissemination are seen more often in 
the USA. Neuroborreliosis is the most frequent manifestation of this stage, particularly in 
its appearance as lymphocytic meningoradiculitis, which usually reveals typical clinical 
symptoms. Cardinal symptoms are the radicular pain syndrome - characterized by 
excruciating, burning pains exacerbating mainly during the night - and/or cranial nerve 
palsy. Pareses of the extremities and the trunk are less frequent. Meningitis or even facial 
palsy (Fig. B-6) as sole manifestation without any meningitic symptoms is more frequently 
found in children than in adults. Typical CSF findings characterized by blood/CSF barrier 
Fig. B-4. Erythema migrans (Source, NRZ Borrelia, http://www.lgl.bayern.de/gesundheit/nrz_borrelien/index.htm)
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dysfunction, lymphocytic pleocytosis, elevated CSF protein concentration and oligoclonal 
IgM are diagnostically indicative. Detection of borrelia-specific intrathecal antibody 
production assures the diagnosis. Further clinical manifestations of stage II are Lyme 
carditis, which clinically presents as dysrhythmia, mainly in the form of atrioventricular 
blocks of changing degrees. Borrelial lymphocytoma, a small reddish to livid nodular 
swelling of the skin in typical locations such as the earlobe, nipple, or scrotum, is 
manifested among some patients in Europe as well as in rare cases various forms of 
ophthalmoborreliosis (Wilske et al., 2007b) (Fig. B-7).  
Fig. B-5. Multiple erythemata (Source, NRZ Borrelia, 
http://www.lgl.bayern.de/gesundheit/nrz_borrelien/inde
x.htm) 
Fig. B-7. Borrelial lymphocytoma. Left, in earlobe; Right, in nipple. (Source, NRZ Borrelia, 
http://www.lgl.bayern.de/gesundheit/nrz_borrelien/index.htm). 
Fig. B-6. Facial palsy of patient suffered from 
neuroborreliosis. (Figure remodeled from Nau 
et al., 2009) 
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3.3 Stage III (months through years after the initial infection) 
Lyme arthritis and acrodermatitis chronica atrophicans (ACA) are the most common 
manifestations of stage III (Fig. B-8). Lyme arthritis, which typically affects large joints 
(especially the knee), can take a monoarticular or oligoarticular, intermittent or, less 
frequently, a chronic course. Here, acute disease manifestations and asymptomatic intervals 
may alternate. Spontaneous remissions are frequent, transitions into the chronic stage rather 
seldom. Patients with ACA initially develop an infiltrative stage, followed by the 
alterations characteristic of the atrophic stage: creased skin with livid discolorations and 
plastic protrusion of vessels. It is notable that ACA is almost exclusively observed in 
Europe. Chronic neuroborreliosis is a very rare manifestation of the late stage. Parapareses 
and tetrapareses are its most common symptoms. Examination of the CSF reveals a marked 
elevation of protein concentration with a low to moderate increase of CSF cells and 
oligoclonal IgG-bands, in some cases even IgA- and/or IgM-bands. The detection of 
intrathecally produced specific antibodies is currently regarded as the best marker for 
borrelial etiology and is also the most relevant criterion allowing differentiation from other 
chronic disease like multiple sclerosis. 
4. Indications for microbiological diagnosis  
If there are no pathognomonic symptoms such as a typical erythema migrans, clinical 
diagnosis of Lyme borreliosis usually requires confirmation by means of a 
Fig. B-8. Lyme arthritis (left) and acrodermatitis chronica atrophicans (ACA) (right) (Source, 
NRZ Borrelia, http://www.lgl.bayern.de/gesundheit/nrz_borrelien/index.htm) 
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laboratory-diagnostic assay.  Antibody detection methods mainly are used for this purpose, 
whereas detection of the causative agent by culture isolation and nucleic acid techniques is 
confined to special situations.  
4.1 Specimens for the microbiological diagnosis  
For culture and PCR, skin biopsy samples are the most promising specimens. In general 
poor results are obtained from body fluids with the exception of PCR from synovial fluid. 
For antibody determination, serum or CSF can be investigated. CSF examination should 
always be done together with serum antibody analysis (determination of the CSF/serum 
antibody index) (Table B-3) (Wilske, 2005). Examination of ticks should be performed 
only for epidemiological or other scientific studies.  
Table B-3. Specimen types used for the diagnosis of Lyme borreliosis (Wilske, 2005). 
 Specimens for 
Clinical manifestation Direct pathogen detection 
(culture, PCR) 
Antibody detection 
Stage I (early / localized), (days through 
weeks after tick bite) 
Erythema migrans 
 
 
Skin biopsy 
 
 
Serum 
Stage II (early / disseminated) (weeks 
through months after tick bite)  
Multiple erythemata 
Borrelial lymphocytoma 
Lyme carditis 
Neuroborreliosis 
 
 
Skin biopsy 
Skin biopsy  
Endomyocardial biopsy  
CSF 
 
 
Serum 
Serum  
Serum 
Paired serum/CSFa 
Stage III (late / persistent) (months through 
years after tick bite) 
Arthritis 
Acrodermatitis chronica atrophicans 
Chronic neuroborreliosis 
 
 
Synovial fluid, synovial biopsy 
Skin biopsy 
CSF 
 
 
Serum 
Serum  
Paired serum/CSFa 
a. from the same day for CSF/serum index determination. 
INTRODUCTION 
 15
4.2 Direct detection of the pathogen 
4.2.1 Culture  
B. burgdorferi s.l. can be cultivated in modified Kelly-Pettenkofer (MKP) or 
Barbour-Stonner-Kelly-II (BSK-II) medium (Preac-Mursic et al., 1991; Wilske and 
Schriefer, 2003; Barbour, 1984). However, it is very time-consuming and characterized by 
a low sensitivity, especially in body fluids (Karlsson et al., 1990; Strle, 1999; Arnez et al., 
2001; Zore et al., 2002). So, detection of the pathogen by culture usually plays a minor role 
in the routine diagnosis of Lyme disease and is confined to special indications, e.g. to 
clarification of clinically and serologically ambiguous findings. Also, application of the 
method should be restricted to laboratories specialized in this technique. 
4.2.2 PCR 
For DNA amplification under experimental conditions various target sequences have been 
used, e.g. from plasmid-borne genes such as ospA and ospB, or chromosomal genes such as 
the genes for the flagellar protein or p66, or from gene segments of the 16S rRNA or the 
5S/23S rRNA intergenic spacer region (Schmidt, 1997; Aguero-Rosenfeld et al., 2005). 
Borrelia PCR should allow diagnosis of the Borrelia species, i.e. the medical report should 
contain information as to which of the species pathogenic for humans has been found.  
4.2.3 Sensitivity of culture and PCR 
Table B-4 provides a survey of the sensitivity of direct detection methods in clinical 
specimens from patients with Lyme borreliosis.  
Table B-4. Sensitivity of direct pathogen detection methods in Lyme borreliosis (Wilske et al., 
2007a)  
Specimen Sensitivity 
Skin (erythema migrans, acrodermatitis) 50–70% when using culture or PCR 
Cerebrospinal fluid (acute neuroborreliosis) 10–30% when using culture or PCR a 
Synovial fluid b (Lyme arthritis) 50–70% when using PCR (culture is only extremely 
seldom positive) 
a
 Up to 50% of patients with a disease duration of less than 2 weeks, compared with only 13% of 
patients with a disease duration of more than 2 weeks (Lebech et al., 2000).  
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b
 Higher sensitivity of direct pathogen detection from synovial biopsy specimens. 
4.3 Antibody detection 
Analysis of the humoral immune response in patients with Lyme borreliosis with regard to 
the immunodominant antigens of B. burgdorferi reveals specific, stage-dependent 
characteristics that are also diagnostically relevant. A positive antibody test result can be 
expected in approx. 20 to 50% of cases with primary-stage Lyme borreliosis. If only a short 
time has elapsed since onset of the disease, mainly IgM antibodies will be found, whereas 
in cases of long-term illness IgG antibodies predominate. Approx. 70 –90% of patients 
going through the secondary stage will show positive antibody test results. In the tertiary 
stage of Lyme disease, antibodies – in most cases of the IgG type only - can be detected in 
almost 100% of patients (Wilske et al., 2007a). It is generally accepted that serological 
examination should follow the principles of a two-step approach (Centers for Disease 
Control and Prevention 1995; Johnson et al., 1996; Wilske et al., 2000; Wilske and 
Schriefer, 2003): In the majority of cases it will be sufficient to conduct a serological 
screening assay and – in the event of a positive or equivocal result – a confirmatory assay is 
recommended (serological stepwise diagnosis). For screening enzyme linked 
immunosorbent assay (ELISA) is mostly used, which, when it is reactive, should be 
confirmed by immunoblot.  
4.3.1 ELISA 
The ELISA tests used for screening should be at least second-generation tests (Wilske et al., 
2000) that have been improved with respect to cross-reactivity with other bacteria (e.g. 
antigen extract with previous Reiter treponema adsorption) (Wilske and Preac-Mursic, 
1993) or use purified intact flagella as antigen (Hansen et al., 1988). Strains used as antigen 
source should express OspC, the immunodominant antigen of the IgM response, and DbpA, 
an immunodominant antigen of the IgG response (Wilske et al., 2000). Recently, specific 
recombinant antigens (i.e. VlsE) or synthetic peptides (i.e. the C6 peptide derived from 
VlsE) have also been successfully used (Lawrenz et al., 1999; Liang et al., 1999, 2000; 
Bacon et al., 2003; Goettner et al., 2005).  
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4.3.2 Immunoblot  
As a confirmatory assay, the immunoblot should have high specificity (at least 95%). In 
whole-cell lysate immunoblots the diagnostic bands are to be specified by the supplier, 
according to their identification with monoclonal antibodies. With the recombinant 
immunoblot this is achieved by selection of the respective specific recombinant antigens. 
For the whole-cell lysate immunoblot the European B. afzelii PKo strain, which is well 
characterized by means of monoclonal antibodies, is recommended as antigen (Wilske et 
al., 2000). In Europe, recombinant immunoblots with quite high sensitivity and specificity 
have been developed by the combination of different antigens and homologues of one 
antigen (Wilske et al., 1999; Panelius et al., 2003; Goettner et al., 2005, Schulte-Spechtel et 
al., 2006) (Fig. B-9). The American immunoblot interpretation criteria (CDC) are not 
suitable for application in Europe (Hauser et al., 1997, 1998; Robertson et al., 2000). 
Interpretation criteria for the immunoblot recommended by the German Society for 
Hygiene and Microbiology (DGHM) are published in the ‘MiQ 12 Lyme-Borreliose’ 
(Wilske et al., 2000) which is available in English via internet 
(http://www.dghm.org/red/index.html?cname5MIQ). For the IgG immunoblot at least 2 
diagnostic bands are required for a positive result, for the IgM immunoblot the existence of 
only one diagnostic band is considered sufficient. 
Fig. B-9. Representative IgG line 
immunoblots of patients with 
neuroborreliosis. Strains belong 
to the following species: B31 and 
PKa2 to Borrelia burgdorferi
sensu stricto; PKo to B. afzelii; 
PBr to B. garinii OspA type 3; PBi 
to B. garinii OspA type 4; 20047 
to B. garinii unknown OspA type. 
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4.3.3 Detection of intrathecally produced antibodies  
The determination of the CSF/serum index should be performed if neuroborreliosis is 
considered, as a positive CSF/serum index confirms present or past involvement of the 
central nervous system. Depending on the time elapsed since the first manifestation of 
neurological symptoms, this method is successful in 80-90% (8-41 days after onset of the 
disease), or even in up to 100% (> 41 days after onset) of cases (Hansen et al., 1991). In 
cases of only short duration, there may be positive CSF findings, while serological results 
are still negative (Christen et al., 1993). A positive antibody index may be detectable as 
long as years after successful therapy and is thus not an appropriate means for monitoring 
treatment success. For diagnosis of late neuroborreliosis detection of a borrelia-specific 
intrathecal IgG-antibody production is obligate and positive in near by 100%. 
5. Treatment of Lyme borreliosis 
Most features of Lyme disease respond to antibiotics. The antibiotic, dosage, duration, and 
route of application depend on the clinical picture and the stage of the disease (Weber and 
Pfister, 1994; Wormser et al., 2006). For EM and borrelia lmphocytoma, oral treatment 
with doxycycline, amoxicillin, or cefuroxime axetil is recommended. Patients with 
acrodermatitis or arthritis receive oral treatment with doxycycline or amoxicillin but in 
cases of poor therapeutic response, patients should be retreated intravenously with 
cephalosporins or penicillin G. Parenteral treatment with ceftriaxone, cefotaxime, or 
high-dose of penicillin G should be performed in the case of severe disseminated infection. 
Intravenous cephalosporins or penicillin G is also recommended for stage Ⅲ 
neuroborreliosis. Antibiotics most often used in treatment of Lyme borreliosis are listed in 
Table B-5.  
Table B-5. Antibiotics most often used for treatment of Lyme borreliosis.  
Clinical manifestation  Antibiotics  Dosage per day Application Duration (day) 
Doxycycline* 1 x 200 mg p.o. 14 
Amoxicillin* 2 x 1000 mg p.o. 14 
Erythema migrans and 
borrelial lymphocytoma 
Azithromycin* 2 x 500 mg p.o. 1 
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 then 1 x 500 mg p.o. 2-5 
or 
Azithromycin* 1 x 500 mg p.o. 10 
Ceftriaxone* 1 x 1g i.m. 5 
Minocycline* 2 x 100 mg p.o. 14 
Cefuroxime* 1 x 500 mg p.o. 14 
 
Penicillin V* 3 x 1 g p.o. 14 
Ceftriaxone* 1 x 2 g i.v. 14 
Cefotaxime* 3 x 2 g i.v. 14 
Acute neuroborreliosis 
and carditis 
Penicillin G* 4 x 3 g i.v. 14 
Ceftriaxone* 1 x 2 g i.v. 21 
Cefotaxime* 3 x 2 g i.v. 21 
Penicillin G* 4 x 3 g i.v. 21 
Arthritis 
Doxycycline* 1 x 200 mg p.o. 28 
Doxycycline* 1 x 200 mg p.o. 21 
Amoxicillin* 2 x 1000 mg p.o. 21 
Ceftriaxone* 1 x 2 g i.v. 21 
Cefotaxime* 3 x 2 g i.v. 21 
Acrodermatitis chronica 
atrophicans 
Penicillin G* 4 x 3 g i.v. 21 
Ceftriaxone* 1 x 2 g i.v. 21 
Cefotaxime* 3 x 2 g i.v. 21 
Chronic neuroborreliosis 
Penicillin G* 4 x 3 g i.v. 21 
*alternative regimens; i.m. = intramuscular; i.v. =intravenous; p.o. = oral. 
Doxycycline should not be used in children younger than 9 years or in pregnant or breastfeeding 
women. 
6. Prevention 
Since the causative agent of the disease is transmitted by ticks, precautions against tick bite 
should be taken by people in endemic areas. Ticks able to transmit the pathogen are small 
and difficult to see. Once attached to the skin, they gorge on blood for days. Transmission 
of B. burgdorferi does not usually occur until the infected tick has been in place for several 
hours. Thus, searching for ticks after potential exposure and removing them can help 
prevent infection. 
In the United States, a vaccine (LYMErix) based on OspA against Lyme borreliosis was 
licensed for use in humans (Steere et al., 1998). In 2002, the producer withdrew the 
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LYMErix vaccine from the market for commercial reasons. However, several other 
effective preventive measures like repellents remain available to persons living in areas 
where the disease is endemic. Antibody raised against another surface-associated protein, 
OspC, has also been shown to protect animals against challenge with homologous B. 
burgdorferi species (Preac-Mursic et al., 1992). Currently, both OspA and OspC vaccines 
are being developed by industry for use in Europe. 
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C. AIMS 
For many bacterial pathogens, binding to their host extracellular matrix molecules such as 
Fn or collagen, is believed to be a critical step for their adhesion to and invasion of host 
tissues. B. burgdorferi can bind to a variety of host extracellular matrix molecules (Joh et 
al., 1999; Menzies, 2003; Cabello et al., 2007; Coburn et al., 2005). A Fn-binding 
adhesin-BBK32 was originally identified by Probert and Johnson (1998). The Fn-binding 
feature of the BBK32 and the biochemical mechanism of its binding in case of B. 
burgdorferi s.s. have already been elucidated (Kim et al., 2004; Probert et al., 2001; 
Raibaud et al., 2005). Overexpression of BBK32 in high-passage B. burgdorferi s.s. strains 
that lacks this protein enhances the organism’s binding to Fn, as well as to 
glycosaminoglycans (Fischer et al., 2006). Furthermore, inactivation of bbk32 gene in 
infectious strains of B. burgdorferi s.s. reduced spirochetal binding to Fn, as well as its 
infectivity in mice (Seshu et al., 2006), although the mutations had no apparent defect in 
tick vectors (Li et al., 2006). These findings suggested that BBK32 might play an important 
role in the adhesion and invasion activities of B. burgdorferi s.s. to its host tissues.  
The Fn-binding site in BBK32 was localized to a 32-amino acid-long segment in the 
protein. This ligand binding segment was shown to share 81–91% amino acid sequence 
identity with the homologous proteins encoded by bbk32 genes of B. burgdorferi s.s., B. 
garinii and B. afzelii (Probert et al., 2001). A former Ph.D student in our laboratory, Dr. 
Christiane Heimerl, found that the BBK32 of B. garinii isolate PHei possesses a stronger 
Fn-binding capacity than that of B. burgdorferi s.s. B31 (C. Heimerl doctoral thesis, 2005). 
From the observation that gelatin can partially inhibit the binding of Fn to BBK32, the 
collagen binding domain of Fn was suggested to contain a binding site for BBK32 (Probert 
et al., 1998).  
B. burgdorferi contains a segmented genome that includes a small, 910 kb linear 
chromosome and as many as 23 circular and linear plasmids, ranging in size from 5 kb to 
56 kb (Fraser et al., 1997; Stevenson et al., 1997; 1998; Casjens et al., 2000; Miller et al., 
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2000). Gene bbk32 is located on the 36kb linear plasmid (lp36) of B. burgdorferi s.s. strain 
B31 (Fraser et al., 1997). Genes carried by lp36 in B31 are often found on 24-29kbp linear 
plasmids in other isolates (Palmer et al., 2000). 
Besides its Fn-binding character, some studies suggested that BBK32 might also be a good 
antigen for the serological diagnosis of Lyme borreliosis (Heikkilä et al., 2002; Lahdenne 
et al., 2003; Panelius et al., 2003; Lahdenne et al., 2006). 
The bbk32 genes are located on linear plasmid and distributed among different B. 
burgdorferi strains. This suggests that these strains have aquired bbk32 by horizontal 
transfer and benefit from the presence of bbk32. However, the role of bbk32 for 
pathogenicities remains to be elucidated. As a first approach in this direction, I investigated 
(i) the presence and location of bbk32 genes in a B. burgdorferi s.l. strain collection, (ii) the 
binding properties of the bbk32-encoding protein for Fn, and (iii) the serum antibodies 
response of patients suffering from Lyme borreliosis against recombinant BBK32. A 
positive antibody response would indicate that BBK32 is expressed during infection and 
that BBK32 could be used for serological diagnosis.   
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D. MATERIALS AND METHODS 
1. Materials 
1.1 Equipments 
Centrifuge Eppendorf centrifuge 5417C, Eppendorf, Hamburg, Germany 
 Sigma centrifuge 4K15, Deisenhofen, Germany  
 Sorvall® RC-5B Refrigerated Superspeed centrifuge, with 
Rotor: SS34, GSA, GS-3, DuPonts Inst. Kendro 
Cycler Gene Amp PCR System 2700, Applied Biosystems, Darmstadt, 
Germany 
Electroblot apparatus Semi-Dry Trans Blot Transfer Cell, BioRad, Munich, Germany 
Electrode Assembly Mini-Protean II Power-Pac 200, BioRad, Munich, Germany 
Electrophoresis chamber Horizontal Agarose gel electrophoresis cell, PeQLab, 
Erlangen, Germany  
ELISA reader SUNRISE, Tecan, Germany 
Film Developing 
Machine 
FUJIFILM FPM-100A, Japan 
Freezer (－20 oC) Profi line, Liebherr, Bulle, Switzerland 
Freezer (－80 oC) Forma Scientific, Inc., Marietta, Ohio, USA 
French Press SLM-AMINCO, Rating cell type, 40K, Spectronic Instruments 
Gel Dryer Model 583 Gel Dryer, BioRad, Munich, Germany 
Heatblock TR-L 288, Liebisch 
Hybridization oven Personal Hyb., Stratagene, Amsterdam 
Incubator Hanau Typ B20, Heraeus Instruments, Hanau, Germany 
Magnetic stirrer RCT basic, Ika Labortechnik, Staufen, Germany 
Microwave LG Electronics, Willich, Germany 
Microscope DIALUX 22, with phase contrast and darkfield, Leitz 
Orbital shaker  OMV ROM, Fröbel Labortechnik, Lindau, Germany 
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PFGE apparatus CHEF-DR Ⅲ, Bio-Rad, Munich, Germany 
pH Meter Accumet basic, Fisher Scientific, Schwerte, Germany 
Photometer Spectrophotometer Ultrospec 3000, Pharmacia Biotech 
Pipettes 2µl, 10µl, 20µl, 100µl, 200µl and 1000µl Pipetman, Gilson, 
France 
 12-Channel 50-300µl Pipette, Labsystems Finnpitette 
Scale MC1 Laboratory LC 220S, Sartorius, Göttingen 
Scanner HP Scanjet 7450C Scanner 
SDS-PAGE apparatus PROTEAN II, Bio-Rad, Munich, Germany 
Shaking incubator Certomat BS-1, B. Braun Biotech International, Melsungen, 
Germany 
Slot blot apparatus Immunetics; Cambridge, MA 
Sterile work bench Hanau Herasafe HS12, Heraeus 
Sterile Filter Units Millipore 
Thermomixer Comfort, Eppendorf, Hamburg, Germany 
Transilluminator UVT-20M/W, Heralab, Wiesloch 
UV-Crosslink GATC-crosslink, Analysetechnique and Consulting Company, 
Konstanz, Germany 
Vortex Reax 2000, Heidolph, Schwabach 
Water bath WB/OB7-45, Memmert, Schwabach, Germany 
1.2 Enzymes  
AmpliTaq® Gold  Applied Biosystems, Darmstadt, Germany 
Antarctic Phosphate*  New England Biolabs, Inc. 
BamHⅠ * Fermentas, Leon-Rot, Germany 
Benzonase  Merck, Darmstadt, Germany 
EcoRⅠ * Invitrogen, Karlsruhe, Germany 
FastDigest™ BsaHⅠ* Fermentas, Leon-Rot, Germany 
FastDigest™ Bst F51* Fermentas, Leon-Rot, Germany 
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FastDigest™ HaeⅢ* Fermentas, Leon-Rot, Germany 
Lysozyme  Roche, Karlsruhe, Germany 
Proteinase K  Roche, Karlsruhe, Germany 
T4 DNA-ligase * Invitrogen, Karlsruhe, Germany 
XhoⅠ* Fermentas, Leon-Rot, Germany 
*Corresponding buffers of these enzymes were also offered by their manufacturers.  
1.3 Molecular weight markers 
CHEF DNA Size Standards (8~48kb)  Bio-Rad, Munich, Germany 
MassRuler™ DNA Ladder (80-1031bp)  Fermentas, Leon-Rot, Germany 
Prestained Protein Molecular Weight Marker  Fermentas, Leon-Rot, Germany 
1.4 Kits 
ELC Direct Nucleic Acid Labelling and Detection 
Systems kit  
Amersham Biosciences, Freiburg, 
Germany 
Glutathione Sepharose 4 Fast Flow  GE Healthcare, Munich, Germany 
High Pure PCR Product Purification Kit  Roche, Karlsruhe, Germany 
High Pure PCR Template Preparation Kit  Roche, Mannheim, Germany 
High Pure Plasmid Isolation Kit  Roche, Karlsruhe, Germany 
1.5 Vectors 
Cloning vector pGEM®-T Easy Vector was purchased from Promega (USA). Expression 
vector was prepared from the recombinant plasmid pGEX-4T-Hq22 (Gao et al., 2007), a 
generous gift from Prof. Dr. Yin Hong from the Lanzhou Veterinary Research Institute, 
Chinese Academy Agricultural Sciences. 
1.6 Antibodies 
Polyclonal Swine Anti-Rabbit IgG/ HRP  Dako Denmark 
Polyclonal Rabbit Anti-Escherichia coli  Dako Denmark 
Polyclonal Rabbit Anti-Human Fibronectin  Dako Denmark 
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Polyclonal Rabbit Anti-Human IgG/HRP Dako Denmark 
Polyclonal Rabbit Anti-BBK32 (B31) antibody  Generated by Pineda Antibody 
Service, Berlin, Germany 
1.7 Bacterial strains 
1.7.1 Escherichia coli 
JM109 Competent Cells  Promega, USA 
BL21(DE3)pLysS strains  Promega, USA 
1.7.2 Borrelia burgdorferi s.l. isolates 
Borreliae were propagated in Modified Kelly Pettenkofer (MKP) medium as previously 
described (Preac-Mursic et al., 1986), all the isolates used in this study were listed in Table 
D-1.  
Table D-1. Borrelia species 
Species Strain Biological 
source 
Geographic 
origin 
OspA type 
B. burgdorferi s.s.  PKa2 K7/+40  CSF Germanny 1 
 PKa2 23/+2 CSF Germanny 1 
 PKa2 23/+16 CSF Germanny 1 
 B31 27/+7  Tick United States 1 
 B31 27/+8  Tick United States 1 
 B31 K4/+5 Tick United States 1 
 N40 52/+10 Tick United States 1 
B. garinii PBi 192/300 CSF Germany 4 
 PBi 109/63 CSF Germany 4 
 PBi 196/9 CSF Germany 4 
 PHei CSF Germany 5 
B. afzelii PKo  Skin (EM) Germany 2 
 PRui  Skin (ACA) Germany 2 
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 PBo CSF Germany 2 
B. spielmanii PMai Skin Germany n.a.* 
 PSig Skin (EM) Germany n.a. 
 PHaP Skin (EM) Germany n.a. 
 ISaue 2  Tick Germany  n.a. 
 DEbelJak Skin (EM) Slovenia n.a. 
 DSM Tick France n.a. 
 PC-Eq17 DSM Tick France n.a. 
 PMew Skin Germany n.a. 
 PAnz Skin Slovenia n.a. 
 PJes Skin Slovenia n.a. 
*n.a., not available. 
1.8 Partially purified recombinant BBK32 proteins 
Four partially purified recombinant BBK32 proteins from strains B31, PKa2, PHei and TN 
were available in the laboratory from previous studies (Heimerl, 2005). 
1.9 Serum panels 
Human serum samples were collected from well-defined clinically Lyme borreliosis 
patients. 24 with erythema migrans (EM), 40 with early neuroborreliosis (NB), and 8 with 
acrodermatitis chronica atrophicans (ACA). Controls comprised 20 sera from healthy blood 
donors, 10 sera from syphilis patients, 10 samples from patients who were positive for 
rheumatoid factor, and 30 sera from patients with fever of unknown origin.  
1.10 Primers 
All oligonucleotides used in the PCR reactions were synthesized by biomers.net GmbH. 
Primers used in this section are shown in Table D-2. 
Table D-2. Oligonucleotides 
Primer no. Primer sequence (5’-3’)a Restriction enzyme sites 
P1 CTGGATCCAGATATGAAATGAAAGAGGA BamHⅠ 
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P2 b CCACTCGAGTTCATCMTCTTCATCAT XhoⅠ 
P3 CACTCGAGATAATCATCTTCATAATA XhoⅠ 
P4 c TACTCGAGGGCGTCATCCCTTTATATTCAT XhoⅠ, BsaHⅠ 
P5 TTGACGCCAAAGAGTTCCTTACAA BsaHⅠ 
P6 b TAGGATCCMAAGGAAGTTTAAATTCCCT BamHⅠ 
P7 ATCTCGAGCCTTAAATCAGAATCTATAGT XhoⅠ 
P8 TAGGATCCCCAAAGAGTTCCTTACAA BamHⅠ 
Forward P 1b CTGGATCCTTATTCAYAAGAKATGAAAT  BamHⅠ 
Reverse P 1b CCC TCG AGT CTA GAT AAG ATT SAT ATC XhoⅠ 
Reverse P 2 TACTCGAGTAGTACCAAACACCATTCTT XhoⅠ 
Forward P2 b TTATTCAYAAGAKATGAAAT  
Reverse P3 b TAACACCYTCTAGATAAGATT  
a. Restriction enzyme sites are underlined. 
b. M could be A or C; Y could be T or C; K could be T or G; and S could be C or G. 
c. The primer contains 2 restriction enzyme sites for different usage. A site-directed silent mutation was 
carried out in order to create BsaHⅠ site, where the Threonine code change from ACT to ACG. The 
mutated nucleotide was framed. 
1.11 Chemicals and other materials 
Acetic acid  Merck, Darmstadt, Germany 
Acrylamid  Biozym, Hameln, Germany 
Albumin Bovine, No. A-7409   Sigma, Deisenhofen, Germany 
6-aminocaproic acid  Sigma, Deisenhofen, Germany 
Ammonium persulphate (APS) BioRad, Munich, Germany 
Ampicillin Biomol, Humburg, Germany 
Ampuwa® (pyrogenfreies Aqua dest. H2Odest)  Fresenius 
Bacto™-Trypton  Becton Dickinson, Heidelberg, 
Germany 
Bisacrylamid  Biozym, Hameln, Germany 
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Bitek™-Agar Difco, Detroit, USA 
Boric acid Merck, Darmstadt, Germany 
Brij 58 Sigma, Deisenhofen, Germany 
Bromphenol blue  BioRad, Munich, Germany 
Calcium Chloride (CaCl2)  Merck, Darmstadt, Germany 
Citric acid (Trisodium salt), No. C-7254 Sigma, Deisenhofen, Germany 
CMRL-1066 (10x) without Glutamine, No. 
042-1540 
Gibco, Gaitersburg. USA 
Coomassie Brilliant Blue R250  Sigma, Deisenhofen, Germany 
Decorin (from bovine articular cartilage)  Sigma, Deisenhofen, Germany 
Diaminobenzidine  Sigma, Deisenhofen, Germany 
Dithiothreitol (DTT)  Biomol, Humburg, Germany 
dNTP Mix Perkin Elmer, Germany 
Ethanol  Merck, Darmstadt, Germany 
Ethidium bromide  BioRad, Munich, Germany 
ethylenediamintetraacetate sodium acid (EDTA)  Merck, Darmstadt, Germany 
Gelatin, Art. 4070  Merck, Darmstadt, Germany 
GenAmp®10×PCR Buffer  Applied Biosystems, Darmstadt, 
Germany 
Glucose, No. G-8270 Sigma, Deisenhofen, Germany 
Glycerin  Merck, Darmstadt, Germany 
Glycine Serva, Heidelberg, Germany 
Hepes, No. H-3375 Sigma, Deisenhofen, Germany 
Human plasma fibronectin  Gibico, Gaitersburg. USA 
Hydrochloric acid (HCl)  Merck, Darmstadt, Germany 
Hydrogen peroxide (H2O2) 30%,  Merck, Darmstadt, Germany 
Incert agarose  Biozym, Hilden, Germany 
Isopropanol Merck, Darmstadt, Germany 
Isopropyl-β-thiogalaktopyranosid (IPTG)  Sigma, Deisenhofen, Germany 
MATERIALS AND METHODS 
 30
methanol  Merck, Darmstadt, Germany 
N-acetylglucosamine, No. A-8625 Sigma, Deisenhofen, Germany 
Neopeptone, No. 0119-01 Difco, Detroit, USA 
N-lauroylsarcosine Sigma, Deisenhofen, Germany 
N, N-Dimethylformamide Sigma, Deisenhofen, Germany 
PMSF  Applichem, Darmstadt, Germany 
Ponceau-S solution  Serva, Heidelberg, Germany 
Potassium dihydrogen phosphate (KH2PO4)  Merck, Darmstadt, Germany 
Potassium phosphate dibasic (K2HPO4 x3 H2O) Merck, Darmstadt, Germany 
Protein Assay Dye Reagent Concentrate  BioRad, Munich, Germany 
Pulsed Field Certified Agarose  Bio-Rad, Munich, Germany 
Pyruvic acid (Sodium pyruvat), No. P-2256 Sigma, Deisenhofen, Germany 
Rabbit Serum, No. 037-06120  Gibco, Gaitersburg. USA 
RNAse A  Roche, Karlsruhe, Germany 
Seakem LE agarose BMA Rockland USA 
SIGMA FAST™ OPD Sigma, Deisenhofen, Germany 
Skim milk powder  Glücksklee 
Sodium acetate (NaAc) Merck, Darmstadt Germany 
Sodium bicarbonate (NaHCO3), No.S-8875 Sigma, Deisenhofen, Germany 
Sodium carbonate (Na2CO3) Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium deoxycholate Serva, Heidelberg, Germany 
Sodium dihydrogen phosphate (NaH2PO4)  Merck, Darmstadt, Germany 
Sodium dodecyl sulphate (SDS)  Sigma, Deisenhofen, Germany 
Sodium hydroxide (NaOH)  Merck, Darmstadt, Germany 
Sodium lauryl sarcosine Sigma, Deisenhofen, Germany 
Sulfuric acid (H2SO4) 95-97%  Merck, Darmstadt, Germany 
Tetramethylethylendiamin (TEMED)  Serva, Heidelberg, Germany 
Thimerosal AppliChem, Darmstadt, Germany 
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Tris (hydroxymethyl) aminomethan (Tris) Sigma, Deisenhofen, Germany 
Triton X 100  Merck, Darmstadt, Germany 
Tween® 20  Serva, Heidelberg, Germany 
Type I collagen (from calf skin)  Sigma, Deisenhofen, Germany 
Urea  Roth, Karlsruhe, Germany 
X-Gal  Biomol, Humburg, Germany 
Xylencyanol Sigma, Deisenhofen, Germany 
All chemicals used in this work had a degree of purity suitable pro analysis. Plastic and 
related articles were purchased from the following companies: Nunc, Roskilde, DK; 
Sartorius, Göttingen; Falco/Becton Dickinson, Heidelberg; B. Braun, Melsungen; 
Eppendorf, Hamburg; Greiner, Nürtingen and Schleicher & Schüll, Dassel. Hybond-N+ 
membranes were purchased from Serva, Heidelberg, NC membranes from PROTRAN, and 
Whatman-paper (3mm) from Whatman Ltd., Maidstone, England. Hyperfilms were 
purchased from Amersham Biosciences, England. 
1.12 Culture media 
10g 
5g 
5g 
Bacto tryptone 
Yeast extract 
NaCl 
Luria-Bertani (LB) broth 
Adjust to pH 7.4-7.6 with NaOH, and add H2Odest to 1 
liter. Autoclave for 20 min at 121 oC. 
10g 
5g 
5g 
15g 
Bacto tryptone 
Yeast extract 
NaCl 
Agar 
Luria-Bertani agar 
Adjust to pH 7.4-7.6 with NaOH, and add H2O to 1 liter. 
Autoclave for 20 min at 121 oC. 
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MKP-Medium  
MKP-Medium was prepared following Table D-3 (Preac-Mursic et al., 1986). 
Table D-3. MKP-Medium  
I CMRL-1066 (10x) without Glutamine 150 ml 
 Dist. water 1350 ml 
 Neopeptone 4.5 g 
 Hepes 9 g 
 Citric acid 10.5 g 
 Glucose 4.5 g 
 Pyruvic acid 1.2 g 
 N-acetylglucosamine 0.6 g 
 Sodium Bicarbonate 3 g 
Adjust to pH 7.6 with 5 N NaOH, sterilize the medium by filtration (0.2µm filter). The 
durability of the Basic Medium (I) lasts for 3 months at －20 oC. 
II 7 % Gelatine (autoclave: 115 oC /15 Min) 300 ml 
 Rabbit Serum - partially hemolyzed (inactivate: 56 oC /30 min) 100 ml 
 Albumin Bovine (35%) 100 ml 
Fill 6.5 ml MKP-Medium into glass tubes (Schott Nr. 26 135 115), or plastic tubes (Falcon 
No. 2027) and close tightly. The durability of the final medium usually lasts for 3 weeks at 
4 oC. Incubate several tubes of the end Medium at 33 oC for 3 days to check if there is 
contamination or not. 
1.13 Softwares and databases 
Microsoft Office 2000 (WORD, EXCEL, POWERPOINT) 
Adobe Reader 8.0 
PDFCreator 
HP Precision Scan Pro3.02 
Lasergene software package for Windows (DNASTAR, Madison, WI) 
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DNAMAN Version 5.2.9 software, Lynnon BioSoft, Canada 
GenBank http://www.ncbi.nlm.nih.gov/Genbank/index.html 
NCBI http://www.ncbi.nlm.nih.gov/ 
PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
ExPASy http://www.expasy.org/ 
2. Methods 
2.1 Molecular biological methods 
2.1.1 Genomic DNA isolation  
Genomic DNA from B. burgdorferi s.s. strain B31, B. garinii strains PBi and PHei, and B. 
afzelii strain PKo was extracted with the High Pure PCR Template Preparation Kit 
according to the manufacturer’s instructions. The final elution volume was 200µl. 
2.1.2 PCR 
PCR was performed in an automatic thermocycler in a 50µl reaction mixture containing: 
Reaction components: GenAmp®10×PCR buffer 
dNTP Mix (2mM) 
Forward primer (20 pmol/µl) 
Reverse primer (20 pmol/µl) 
AmpliTaq Gold™ 
Template DNA 
H2O 
5µl 
8µl 
0.5µl 
0.5µl 
0.5µl 
5µl 
30.5µl 
Cycling parameters: Denaturation 95°C 
Denaturation* 95°C 
Annealing* Tm 
Elongation* 72°C 
3 min 
1 min 
1min 
1min 
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Final extension 72°C 7min 
* 30 cycles 
Tm: Annealing temperature dependent on the Tm (melting temperature) of primers 
2.1.3 Agarose gel electrophoresis 
The agarose gels with different concentrations (1% to 2.5%) were prepared by mixing an 
appropriate proportion of agarose with 1 x TAE buffer, the mixture cooked and after 
cooling poured into precast agarose gel chambers. The DNA was then mixed with loading 
buffer, loaded onto spurs on the gel and electrophoretically resolved by voltage application 
utilizing the 1 x TAE solution as the running buffer. Following the electrophoretic run, gels 
were stained in ethidium bromide solution (1µg/ml) and the DNA visualized under 
ultraviolet radiation. 
Solutions: 
1x TAE buffer 40mM Tris / HCl, pH = 8.2 
20mM Acetic acid 
2mM EDTA, pH 7.6 
Loading buffer for agarose gel 0.25 % (w/v) Bromophenol blue 
0.25 % (w/v) Xylencyanol 
30 % (w/v) Glycerin  
20 mM Na2EDTA  
2.1.4 Recovery of DNA fragments from agarose gel 
Agarose gel electrophoresis separated target DNA fragments were cut from the gel under 
ultraviolet radiation and recoveried using a High Pure PCR Product Purification Kit 
following the manufacturer’s instructions. 
2.1.5 Enzymatic modification of DNA 
2.1.5.1 Restriction digestion of DNA 
Restriction endonuclease digestion of chromosomal or plasmid DNA samples were 
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performed as below: 
BamH  and Ⅰ XhoI double digestion EcoRⅠ digestion 
DNA 
10X Buffer Bam HI 
Bam HI 
Xho I 
H2O 
Xµl 
1µl 
0.5µl 
1µl 
to 10µl* 
DNA 
10X Buffer EcoRI 
EcoRI 
H2O 
Xµl 
1µl 
1µl 
to 10µl* 
Incubate at 37°C for 1 or 2 h.  
*The higher concentration of DNA, the more amount of H2O. 
 
FastDigest® restriction enzyme digestion 
DNA 
10× FastDigest® buffer 
Restriction enzyme* 
H2O 
xµl 
1µl 
1µl 
to 10µl** 
Incubate at 37°C for 5min. 
*the enzymes are FastDigest™ Bsa HⅠ, FastDigest™ Bst F51 or FastDigest™ HaeⅢ. 
** The higher concentration of DNA, the more amount of H2O. 
2.1.5.2 Dephosphorylation of DNA 
To prevent self-religation or dimerization of a restriction endonuclease linearized vector, its 
5'-phosphate groups were removed with Antarctic Phosphatase (as shown below) following 
the manufacturer’s instruction. The vector DNA is then free to ligate with an insert DNA of 
choice.  
NE buffer for Antarctic Phosphatase 
Antarctic Phosphatase 
Linearized vector 
1µl 
2µl 
7µl 
Thoroughly but gently mixed and incubated at 37°C for 30 min, followed by heat 
inactivation at 65°C for 5 min.  
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2.1.5.3 Ligation of DNA molecules 
Ligation of an insert into arms of a vector or ligation of two DNA fragments to construct a 
longer linear DNA fragment was carried out with the enzyme T4 DNA ligase as described 
below:  
Ligation of purified PCR products into pGEM®-T easy vector (TA cloning) 
2× Rapid Ligation Buffer, T4 DNA Ligase 
pGEM®-T Easy Vector (50ng) 
PCR product 
T4 DNA Ligase (3 Weiss units/µl) 
5µl 
1µl 
3µl 
1µl 
Mix the reactions by pipetting and incubate at 4 oC overnight. 
   
Ligation of DNA inserts into linearized pGEX vector 
5×T4DNA ligase buffer 
pGEX vector 
Insert  
T4DNA ligase (1 Weiss units/µl)  
Incubate at 16 oC overnight. 
2µl 
2µl 
5µl 
1µl 
 
Ligation of two DNA fragments with similar sizes 
5×T4DNA ligase buffer 
Fragment 1 
Fragment 2 
T4DNA ligase (1 Weiss units/µl)  
Incubate at 16 oC overnight. 
2µl 
3.5µl 
3.5µl 
1µl 
2.1.6 Preparation of Escherichia coli BL21 competent cells 
Competent cells were prepared as described by Sambrook (2001). One single colony of 
Escherichia (E.) coli BL21(DE3)pLysS was inoculated into 5 ml LB broth and was 
incubated overnight at 37 oC and 200 rpm. On next day, the 5 ml overnight culture was 
inoculated into 250ml LB broth and incubated at 37 oC with vigorous shaking until an 
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OD600 of 0.6 was achieved (about 3h). The following steps were performed on ice. After 
being chilled on ice for 10 min, the culture was centrifuged at 4 oC and 4000 rpm (3220 rcf) 
for 10 min. All supernatants were discarded and the sediments were resuspended with 125 
ml 0.1M CaCl2 and again chilled on ice for 45 min. Chilled cells were centrifuged at 4 oC 
and 4000 rpm (3220 rcf) for 10 min and supernatants were discarded. The pellets were 
resuspended with 4 ml ice chilled 0.1M CaCl2 and 1ml glycerol and 100 µl aliquots of the 
bacterial suspension was put into 1.5 ml Eppendorf tubes. All the aliquots were stored at 
－70°C till usage. 
2.1.7 Bacterial transformation  
2.1.7.1 Transformation into E. coli JM109  
Ten-microliter of ligation product was gently mixed with 50µl E. coli JM109 competent 
cells and chilled on ice for 20min. After a 1 min heat-shock at exactly 42 oC, the 
transformation mixture were again chilled on ice for 3 min. LB broth at room temperature 
was added to the tubes containing cells transformed with ligation reactions to a final 
volume of 1 ml and incubated at 37 oC for 1.5 h with gentle shaking (~150 rpm). A hundred 
microliters of transformation culture was spread onto an LB agar plate containing 200 
µg/ml of ampicillin (for pGEM-T easy vector, IPTG and x-gal were also required, see 
below). The rest 900µl culture was centrifuged at 3000 rpm for 3 min and its pellet was 
cultivated onto another LB agar plate. Plates were incubated at 37 oC overnight. 
Preparation of LB/ampicillin/IPTG/X-gal agar plate: 
Spread 17µl of 200mM IPTG and 40 µl of X-gal (20 mg/ml in 100 % N, 
N-Dimethylformamide) onto the surface of an LB agar plate (ø 9 cm) containing 200 µg/ml 
of ampicillin. 
2.1.7.2 Transformation into E. coli BL21  
One-microliter of isolated plasmid was gently mixed with 100µl E. coli BL21(DE3)pLysS 
competent cells. The following steps were the same as transformation of E. coli JM109 
cells only with an exception of no IPTG and X-gal adding to the plates.  
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2.1.8 Recombinant plasmid purification 
Three or five E. coli white colonies were picked from each plate and inoculated into LB 
broth (supplied with ampicillin) and cultivated overnight at 37 oC. Plasmids were isolated 
from the overnight culture by using the High Pure Plasmid Isolation Kit according to the 
manufacturer’s instructions.  
2.1.9 Confirmation of inserts  
Isolated recombinant plasmids were first digested with BamHⅠ and  XhoⅠ or EcoRⅠ. 
Plasmids conceiving inserts with expected sizes confirmed by restriction enzyme digestion 
were sequenced by using the SP6 and T7 primers by Qiagen Company.  
2.1.10 Pulsed field gel electrophoresis (PFGE) 
2.1.10.1 Preparation of Borrelia DNA in agarose blocks 
Borrelia DNA was prepared after embedding the bacterial cells in agarose as described 
previously (Busch et al., 1995) with some modifications. Cells were washed four times and 
resuspended in TN buffer (10mM Tris, pH 7.6, 1M NaCl) to approximately 1 × 109 
cells/ml. Equal volumes of cells and 2% Incert agarose were mixed at 56°C. Cell-agarose 
suspension was filled into a mould and incubated at 4°C. The solidified agarose blocks 
were incubated in a lysis solution (1M NaCl, 20mM Tris-HCI, pH 8.0, 0.1M EDTA Na2, 
0.5% Brij-58, 0.2% sodium deoxycholate, 0.5% N-lauroylsarcosine, 10µg/ml RNAse A, 1 
mg/ml chicken lysozyme) for 30 min at 4°C. The agarose blocks were washed with TE 
buffer (20mM Tris-HCl, pH8.0, 50mM EDTA Na2) at 4°C for 1 h and digested with 
digestion buffer (0.5mg/ml Proteinase K, 10mM EDTA, pH8.0, 0.2% sodium deoxycholate, 
1% sodium lauryl sarcosine) at 50°C for 72 h with gentle shaking. The agarose blocks were 
washed 3 times (1 h for each wash) with TE buffer at 4°C and stored at 4°C. 
2.1.10.2 Gel electrophoresis 
PFGE was done with a CHEF (contour-clamped homogeneous electric field), DR (dynamic 
regulated) Ⅲ at 14°C in 0.5 X TBE (45mM Tris-borate, 1mM EDTA), with 6 V/cm and 
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an electrode angle of 120° with buffer circulation. Half of an agarose block was placed into 
the sample well of a pre-cast 1% Pulsed Field Certified Agarose gel and sealed with 1% 
Incert agarose. Separation of plasmids was carried out with a pulse time of 3 s for 30 h. 
CHEF DNA Size Standards (8~48 kb) was used as a size ladder. The gel was stained with 
ethidium bromide (EtBr) and photographed under ultraviolet transillumination. For 
southern blot, placing a ruler near the marker was necessary.  
10×TBE: 
Tris base 
EDTA Na2 
Boric acid 
108g 
7.44g 
55g 
Add water to a final volume of 1 liter and pH 8.3 obtained.    
2.1.11 Southern blot 
After depurinization (in 0.25M HCl), denaturation (in 0.5M NaOH and 1.5M NaCl) and 
neutralization (in 0.5M Tris-HCl, pH 7.5, and 1.5M NaCl), DNA was transferred to a 
Hybond-N+ membrane by capillary force and UV cross-linked to the membrane with the 
GATC-crosslink. 
2.1.12 Preparation of labeled probe 
Purified PCR product was labelled with the ELC Direct Nucleic Acid Labeling reagent 
according to the manufacture’s instructions. Briefly, PCR product (10 ng/µl) was boiled for 
5 min and then chilled on ice for 5min. An equivalent volume of DNA labeling reagent was 
added to the cooled DNA and mixed gently but thoroughly. The glutaraldehyde solution 
(the same volume as that of the labeling reagent) was then added to the mixture and spun 
briefly in a microcentrifuge to collect the contents at the bottom of the tube. After 
incubation for 10min at 37°C, the mixture was again chilled on ice and mixed with equal 
volume of glycerol. The prepared probe can be store at －20°C till required. 
2.1.13 DNA hybridization and detection 
DNA hybridization and detection of the DNA probe were performed using ELC Direct 
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Nucleic Acid Labelling and Detection Systems kit following the manufacturer’s 
instructions. Briefly, three bbk32 PCR fragments were labelled with horseradish peroxidase. 
Prehybridization (for 1h) and hybridization (overnight) were done in the hybridization 
buffer (with 0.5M NaCl and 5% [w/v] blocking agent) at 42°C. The three probes were 
mixed and used at a concentration of 10 ng/ml for each probe. Blots were then washed 
twice (20 min for each washing) with primary wash buffer (0.5×SSC, 6M Urea, 0.4% SDS) 
at 42°C and twice with secondary wash buffer (2×SSC) (5 min for each) at room 
temperature. To visualize positive signals, the blot was incubated for 1 min in a freshly 
prepared detection mixture of the ECL detection reagents and positive signals were 
exposed to a sheet of Hyperfilm ECL film at room temperature.  
20×SSC:  
Na3citrate  
NaCl 
pH 7.0 (adjust with 1M HCl) 
0.3M 
3M 
2.2 Biochemical methods 
2.2.1 IPTG induction for protein over expression 
Three colonies were picked from each plate, inoculated into LB broth (containing   200 
µg/ml ampicillin) and cultivated at 37°C overnight. Then 50µl overnight culture was 
cultivated at 37°C in 5 ml fresh LB broth (with ampicillin adding) with vigorous shaking 
(~230 rpm) for 3 hours. The culture was then provided with IPTG to a final concentration 
of 2 mM and incubated at 28°C for additional 5 h. 
2.2.2 Sodium-dodecyl-sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Proteins were fractionated by sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) 
using a 12.5% resolving gel and 4% stacking gel (components see below). The 
electrophoresis system from Bio-Rad was employed in this work and the assembly of glass 
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plates and spacers for the production of the gels was according to manufacturer’s 
instructions. Before electrophoresis, protein samples were treated with protein loading 
buffer, boiled at 95°C for 5 min and loaded into the slots of the gel. The electrophoresis 
was run at 180 V until the bromophenol blue reached the edge of the gel in a 
Tris/glycine/SDS running buffer system (pH 8.3). Prestained Protein Molecular Weight 
Marker was used for the estimation of the molecular mass. Resolved proteins were either 
viewed directly by staining the gel with Coomassie brilliant blue or transferred to 
Nitrocellulose (NC) membrane and subjected to Western blot analysis or examined in a 
Fn-binding assay. Destained gels were dried using a Gel dryer for 2 h and scanned. All the 
related solutions and buffers were listed below.  
 
25% Acrylamid/ Bis acrylamid (4oC) 40% Acrylamid  
2% Bisacrylamid  
H2O 
 
60.83ml 
33.5ml 
5.67ml 
SDS separation gel (for 2 mini-gels) H2O 
1.5M Tris, pH8.8 
10% SDS 
25% Bis-Acrylamid 
10% APS 
TEMED 
Total volume 
2.35ml 
2.5ml 
100µl 
5.0ml 
50µl 
5µl 
10ml 
 
SDS stacking gel (for 2 mini-gels) H2O 
0.5M Tris, pH6.8 
10% SDS 
25% Bis-Acrylamid 
10% APS 
TEMED 
Total volume 
2.89ml 
1.25ml 
50µl 
0.78ml 
25µl 
5µl 
5ml 
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10×SDS-PAGE running buffer 
(1:10 dilution before usage) 
Tris-base 
Glycine 
SDS 
H2O 
30g 
144g 
10g 
till 1liter 
 
2×Protein loading buffer (store at －
20oC) 
H2O 
0.5 M Tris-HCl pH 6.8 
Glycerin 
10% SDS 
Dithiothreitol (DDT) 
Bromphenol blue              
4.6ml 
1.0ml 
0.8ml 
1.6ml 
8g 
0.05% (w/v) 
 
Gel fix solution 30% (v/v) Ethanol  
10% (v/v) Acetic acid 
 
Coomassie Brilliant Blue solution 0.5% (w/v) Coomassie Brilliant Blue (R250) 
10% (v/v) Acetic acid 
45% (v/v) Methanol 
 
SDS-gel Destaining solution 10% (v/v) Acetic acid  
25% (v/v) Methanol 
 
2.2.3 Western blot 
Electrophoretic transfer of proteins from polyacrylamide gels to a NC membrane was 
performed using the Semi-Dry Trans Blot Transfer Cell. As shown in Fig. D-1, the blotting 
sandwich was prepared in the following order: from anodic pad to cathodic, 6 layers of 
filters soaked in anodic solution I (0.3 mol/L Tris buffer, 20% methanol [v/v], pH 10.5), 3 
layers of filters soaked in anodic solutionⅡ (25 mM Tris buffer, 20% methanol, pH 10.4), 
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anodic solutionⅡmoistened NC membrane, cathodic solution equilibrated SDS-PAGE gel 
and 6 layers of filters soaked in cathodic solution (40 mM 6-aminocaproic acid, 20% 
Methanol, pH 7.5). Electrophoresis was performed at 60 mA constant current for 45 min 
per mini-gel. Protein transfer was controlled by staining the membranes with Ponceau S 
solution. Detection of proteins in a NC membrane was accomplished by using antibodies. 
Briefly, unbound sites of the membrane were blocked in blocking solution (5% milk in 
TBST [10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20]) for 1 h at 37°C to 
suppress non-specific adsorption of antibodies. The membrane was then incubated 
overnight with fist antibody (negative serum, rabbit anti-E. coli polyclonal serum or rabbit 
anti-BBK32B31 polyclonal serum) with a dilution of 1:750 at room temperature, followed 
by a 1:1.000 dilution of swine anti-rabbit IgG-horseradish peroxidase (HRP) conjugate for 
2 hours. The dilution solution for both the first and the secondary antibody were TBST 
containing 1% milk. Between incubations, membranes were washed three times with TBST, 
10 min for each washing. Positive signals were detected with 0.5mg/ml diaminobenzidine 
solution (see below) and the reaction was stopped by 1N sulfuric acid (H2SO4). 
 
0.5 mg/ml diaminobenzidine solution 
 
Diaminobenzidine 
1M Tris pH 7.4 
H2O 
Just before usage, add 50µl of 30% H2O2. 
50mg 
5ml 
95ml 
 
Fig. D-1. Diagram of preparing the gel sandwich 
NC membrane 
Anodic solutionⅠsoaked filters  
 
 
SDS-PAGE gel 
Anodic solutionⅡsoaked filters 
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2.2.4 Purification of recombinant proteins 
2.2.4.1 Cell extract preparation 
About 30 ml overnight culture of E. coli BL21(DE3)pLysS expressing expected 
recombinant protein was inoculated into 500 ml LB broth under ampicillin selection and 
incubated at 37°C with shaking for 2-3 h till an OD600 of 0.7-1.0 was achieved. The cells 
were then induced with 0.2mM IPTG for another 5 hours at 28°C. Cells were pelleted by 
centrifugation at 7.000 rpm for 10 min at 4°C, and the pellet were thoroughly resuspended 
in binding buffer (50 mM Tris-HCl pH 7.5, 0.3M NaCl, 1mM DTT and 0.1% Triton X-100) 
and brought to a final volume of 28ml. Then 10µl Benzonase and 280µl of 0.2 M PMSF 
were added to the suspension. The cell extracts were always kept on ice. 
2.2.4.2 Lysis of E. coli by high pressure (French Press) homogenization 
The suspended cells were broken at 1.000 psi by passing through a French Press cell for 3 
times. Cell lysate was chilled on ice between runs. Following breakage, lysed samples were 
centrifuged at 15.000 rpm for 30 min at 4°C (Sorvall Rotor SS34) and the supernatant 
was ready for protein purification. 
2.2.4.3 Batch purification 
Supernatant containing recombinant proteins were transferred to 5 ml Glutathione 
Sepharose 4 Fast Flow beads balanced by Binding buffer beforehand and incubated on ice 
for 4 hours with gentle agitation. Unbound proteins in the supernatant after centrifugation 
at 500×g for 5 min were transferred to another freshly prepared beads for a second round 
of purification. After being washed with Binding buffer (50 mM Tris-HCl pH 7.5, 0.3M 
NaCl, 1mM DTT and 0.1% Triton X-100) for 3 times, proteins bound to beads were eluted 
with 10 ml Elution buffer (30mM glutathione, reduced [GSH], pH8.4) on ice for 2 hours. 
Supernatant containing the purified fusion protein was carefully harvested after 
centrifugation of the slurry at 500×g for 5 min.  
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2.2.4.4 Protein purification with polyacrylamide gel 
Some proteins, after a first round of purification, were still not pure enough. Thus a second 
round of purification with polyacrylamide gel was also performed. Briefly, proteins from 
the first round purification were resolved on a 12.5 % SDS-PAGE gel and transferred to a 
NC membrane. After being stained with Ponceau S solution, target protein bands were cut 
from the membrane and eluted with nonvolatile solution (50mM Tris-HCl, pH9.0, 2% SDS 
[w/v], 1% Triton X-100 [v/v]) at room temperature for 1 hour with rotating. Eluted proteins 
were concentrated using Vivaspin Concentrators (GE Healthcare) following the 
manufacturer’s instruction. 
2.2.5 Protein concentration determination 
Protein concentrations were determined by the Bradford method (Bradford, 1976) using 
bovine serum albumin (BSA) as protein standard. Briefly, six dilutions of a protein 
standard BSA were prepared and 200 µl of dye reagent concentrate was added to each tube 
containing 800 µl of each standard and mixed well. After an incubation of 5 minutes at 
room temperature, absorbance at 595 nm of the protein-dye mixture was measured using a 
spectrophotometer set. A standard curve was thus prepared according to the standard 
concentrations and their absorbance at 595 nm. Concentrations of purified proteins were 
then determined by measuring absorbance at 595 nm after appropriate dilution.  
20×PBS pH7.4 
NaCl 
K2HPO4×3 H2O 
KH2PO4 
78.85g 
34.25g 
3.9g 
Solved to a final volume of 500ml with H2O, 1:20 diluted before requirement. 
 
2.3 Line assay 
For the line assay, each recombinant antigen was individually dissolved in anodic solution
Ⅱ(25 mM Tris buffer, 20% Methanol, pH 10.4), and loaded into a separate line of a slot 
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blot apparatus (Miniblotter 45, Immunetics; Cambridge, MA). Proteins were then allowed 
to bind in horizontal lines to the membrane for 3 hours at room temperature. Protein 
binding was assessed by staining membranes with Ponceau-S. After being destained with 
distilled water and blocked in blocking solution (5% milk in TBST), the membranes were 
cut vertically into 3- to 4-mm-wide strips and incubated overnight at room temperature 
with human sera diluted 1:200. Bound antibody was detected with horseradish 
peroxidase-labeled rabbit anti-human IgG secondary antibody. Between incubations, 
membranes were washed three times with TBST, 5 min for each washing. Positive signals 
were detected with 0.5mg/ml diaminobenzidine solution and the reaction was stopped by 
1N sulfuric acid (H2SO4) (all the buffers were the same as in section 2.2.3). 
2.4 Fn-binding assays 
2.4.1 Western-ligand blot-based binding assay 
Proteins were separated by SDS-PAGE gel and transferred to NC membranes. The 
membranes were incubated first with 5µg/ml human Fn, then with a 1:500 dilution of 
polyclonal rabbit anti-human Fn, and finally with a 1:1.000 dilution of polyclonal swine 
anti-rabbit immunoglobulins/ HRP conjugate (in TBST). Prior to the first incubation, 
membranes were blocked with 5% milk in TBST for 1 hour at 37°C. Between incubations, 
membranes were washed three times with 10ml TBST. Membranes were developed using 
0.5mg/ml diaminobenzidine and stopped by 1N H2SO4. 
2.4.2 Immunoblot-based inhibition assays 
On the one hand, purified proteins (0.5 µg/lane) were separated by SDS-PAGE gel and 
electroblotted onto NC membrane. On the other hand, strips carrying the purified proteins 
(100 µg/ml) for line assay were prepared as described in section 2.3. Prior to incubation 
with Fn, the blots or strips were first incubated with increasing concentrations of either 
collagen, gelatin, BSA or decorin (in TBST buffer) for 1 h at 37°C. The following steps 
for binding assays were the same as in section 2.4.1. 
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2.4.3 ELISA-based binding assay  
An enzyme-linked immunosorbent assay (ELISA)-based Fn-binding test was also 
performed. Briefly, Nunc 96-well microtitre plates were coated with the different purified 
recombinant proteins (0.01 or 0.05 µg/well) and incubated overnight at 4°C in 0.1 M 
carbonate buffer, pH 9.6. The plates were washed in washing buffer consisted of PBS 
containing 0.05% (v/v) Tween 20 (PBST) and then blocked for 1 h with 5% skimmed milk 
powder in 0.1 M carbonate buffer. After blocking, the plates were incubated first with 
human Fn (0.1 or 0.2 µg/ml in PBST), then with a 1:800 dilution of polyclonal rabbit 
anti-human Fn, and finally with a 1:1.000 dilution of polyclonal swine anti-rabbit 
immunoglobulins/ HRP conjugate. Each incubation was performed at 37°C for 1 hour. 
Between incubations, the plates were thoroughly washed for 4 times with washing buffer. 
After a final wash, 200 µl of o-phenylenediamine dihydrochloride (SIGMA FAST™ OPD) 
substrate (to dissolve one OPD tablet and one urea hydrogen peroxide/buffer tablet in 20 ml 
of water to get a final concentration of 0.4 mg/ml OPD, 0.4 mg/ml urea hydrogen peroxide, 
and 0.05 M phosphate-citrate, pH 5.0) was added to each well and incubated in the dark for 
30 min at room temperature. Reactions were then stopped by adding 50 µl of 3 M H2SO4 to 
each well and the absorbance was measured at 492 nm in an ELISA reader.  
2.4.4 ELISA-based inhibition assay 
To map the functional domain of Fn that interacts with BBK32 proteins, as described above, 
the microtitre plates were coated with purified proteins with an amount of 0.05µg protein 
per well and blocked with skimmed milk powder solution. Before adding to the plates, 
human Fn (0.1 µg/ml) was incubated for 1h at 37°C with diluent only or increasing 
concentrations of either BSA, gelatin or collagen. After this incubation step, the Fn was 
added to the plates. The following steps for binding assays were the same as in section 
2.4.3. 
2.4.5 Statistical analysis 
In ELISA based binding assays, for each concentration of proteins three independent 
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experiments (each in duplicate) were performed. For each concentration of Fn, 3 assays in 
duplicate were conducted. In the ELISA based inhibition tests, for each concentration of 
gelatin, collagen or BSA, three independent assays (each in duplicate) were carried out. 
Average of the absorbance value from the duplicate wells in each independent experiment 
was calculated first. Later, mean and standard deviation (SD) of the three averages were 
calculated. The two sets of averages (each with 3 numbers) from two different proteins 
were analyzed using Student’s t-test. Statistical significance was accepted when the 
P-values were less than 0.05. 
2.5 Sequence analysis 
BLAST-search analysis was used for the search of homologous sequences. Sequence 
alignment was carried out with the Lasergene software package for Windows (DNASTAR, 
Madison, WI) or with the DNAMAN version 5.2.9 software. 
2.6 GenBank accession numbers 
GenBank accession numbers of bbk32 genes related to this study are listed in Table D-4. 
Table D-4. GenBank accession numbers of bbk32 genes 
Species Isolate Accession number 
B31 NP_045605 
156a   YP_002477384 
IA  AF472532 
B. burgdorferi s.s.  
PKaⅡ FJ997275 
PHei FJ804148 
PBi FJ997277 
TN FJ997278 
50  AF472531 
40  AF472529 
B. garinii 
46  AF472530 
B. afzelii PKo FJ997276 
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ACA-1  YP_002455579 
570  AF472526 
600  AF472528 
1082  AF472527 
 
A91  AF472525 
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E. RESULTS 
1. Localization of the bbk32 gene in the genomes of different B. 
burgdorferi s.l. strains 
Borrelia burgdorferi s.s. contains a segmented genome that includes a small, 910 kb linear 
chromosome and as many as 23 circular and linear plasmids, ranging in size from 5 kb to 
56 kb (Fraser et al., 1997; Stevenson et al., 1997; 1998; Casjens et al., 2000; Miller et al., 
2000). The lp36 plasmid of strain B31 is a linear plasmid of approximately 36kb encoding 
54 putative open reading frames (ORFs), seven of which appear to be pseudogenes (Fraser 
et al., 1997; Casjens et al., 2000). Of the few genes on lp36 that have a putative function 
(Casjens et al., 2000), bbk32 has been shown to encode a Fn-binding protein (Probert and 
Johnson, 1998; Probert et al., 2001) that may be involved in B. burgdorferi s.s. mammalian 
infectivity (Li et al., 2006; Seshu et al., 2006). Former study suggested genes carried by 
lp36 in B31 are often found on 24-29kbp linear plasmids in other isolates (Palmer et al., 
2000). Here we described the plasmid profile of more than twenty isolates of four 
pathogenic borrelial species and the distribution of bbk32 genes on these plasmids by 
PFGE and southern blot. 
1.1 Probes for hybridization 
To prepare bbk32 probes, gene fragments of bbk32 with sizes of around 580 bp were 
generated by PCR (Fig. E-1) amplification of genomic DNA isolated from B. burgdorferi 
s.s. B31, B. garinii PBi, and B. afzelii PKo with gene specific primer pairs (Forward P2 and 
Reverse P3) and confirmed by sequencing. Comparison of the 3 fragments was shown in 
Fig. E-2. The fragments of bbk32 from those isolates shared identities from 82.6% to 
92.6%. The three bbk32 PCR fragments were then labeled with horseradish peroxidase and 
mixed at a concentration of 10 ng/ml for each probe to hybridize bbk32 genes on the 
genome of a various of strains of B. burgdorferi s.l.. 
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Fig. E-2. Sequences of the three bbk32 fragments used as probes for hybridization. Residues that 
match B31 seq. exactly were hided as “.”.  
M   B 3 1  P B i  P K o
bp
1031
900
800
700
600
500
400
580bp 
Fig. E-1. Amplified bbk32 gene fragments for preparing the probes  
PCR products amplified from genomic DNA from isolates B31, PBi and PKo were resolved through 
a 2% agarose gel. Lane
 
M was the DNA standard ladder. 
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1.2 Localization of bbk32 among strains 
Genomic DNA of 23 isolates of B. burgdorferi s.l. were separated by Pulsed Field Gel 
Electrophoresis (PFGE) and transferred onto Hybond-N+ nylon membrane and bbk32 
genes were probed with the above prepared probes. Results in Fig. E-3 showed that the 
localizations of bbk32 were quite various among different species, and even in one species, 
the localization was different from strains. As previously reported, bbk32 was localized on 
the 36 kbp linear plasmid (lp36) of B. burgdorferi s.s. B31 (Fraser et al., 1997) and the 
same pattern was seen in strain PKa2 (K7/40), however the localization of the gene was on 
a plasmid with a size of around 32kb in strain N40 (Fig. E-3, a). bbk32 was localized to the 
25kbp linear plasmid in both B. garinii (PBi) and B. afzelii (PKo). The gene was not 
detected in strains PRui and PBo (Fig. E-3, b and c), In B. spielmanii, signals were detected 
on plasmids with comparable sizes between 23kbp and 28kbp by using the bbk32 probes. 
Hybridization signals were not obtained from strains PMai, PSig and DSM (Fig. E-3, d).  
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Fig. E-3. Detection of the bbk32 gene in the genomes of Borrelia burgdorferi s.l. strains.  DNAs 
from representative B. burgdorferi s.l. isolates (indicated above each lane) were separated by PFGE, the 
gel was stained with ethidium bromide (left panel in each group), and the DNA was transferred onto 
membranes for hybridization analysis with labeled bbk32 probes (right panel in each group). a, B. 
burgdorferi s.s strains; b, B. garinii strains; c, B. afzelii strains; and d, B. spielmanii strains. 
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2. Comparative assay of Fn-binding capacities of BBK32 
proteins from B31 and PHei 
For many bacterial pathogens, attachment to their host tissues is believed to be a critical 
step during colonization and is typically mediated by adhesins, i.e., surface proteins that 
promote bacterial attachment to host cells (Finlay et al., 1997; Joh et al., 1999; Menzies, 
2003). For B. burgdorferi s.l., their infectious processes require mobilization from the tick 
vector following a blood meal into a mammalian host where colonization occurs within the 
dermis (Duray, 1989; Asbrink et al., 1990; Malane et al., 1991). This location is rich in 
extracellular matrix (ECM) molecules such as Fn, collagen, and elastin (Cabello et al., 
2007; Coburn et al., 2005). Following deposition in the dermis, Borreliae bind to host 
ligands from which they replicate and disseminate throughout the infected host. Most 
strikingly, it has become clear that the pathogens encode several adhesion molecules 
including the Fn-binding protein BBK32, the decorin-binding proteins DbpA and DbpB, 
the integrin-binding protein P66, and the glycosaminoglycan-binding protein Bgp (Coburn 
et al., 1999; Guo et al., 1998; Parveen et al., 2000; Probert et al., 1998). All these 
molecules might run a role in promoting the attachment of Borreliae to cell surfaces or to 
components of ECM, reinforcing the notion that adhesion is critical to the biology of B. 
burgdorferi and the pathogenesis of Lyme disease (Fig. E-4) (Coburn et al., 2005).   
The Fn-binding protein BBK32 was originally identified by Probert and Johnson (1998). 
The Fn-binding feature of the BBK32 and the biochemical mechanism of the binding have 
already been elucidated (Kim et al., 2004; Probert et al., 2001; Raibaud et al., 2005). 
Overexpression of BBK32 protein in high-passage B. burgdorferi strain that lacks this 
protein enhances the organism’s binding to Fn, as well as to glycosaminoglycans (Fischer 
et al., 2006). Furthermore, inactivation of bbk32 gene in infectious strains of B. burgdorferi 
reduced spirochetal binding to Fn, as well as its infectivity in mice (Seshu et al., 2006), 
although the mutations had no apparent defect in tick vectors (Li et al., 2006). These 
findings suggested that BBK32 might play an important role in the adhesion and invasion 
activities of B. burgdorferi to its host tissues. 
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BBK32 consists of a C-terminal globular domain and an N-terminal region lacking 
well-defined secondary structure (Kim et al., 2004). In prior studies, the Fn-binding 
activity of BBK32 was localized to a 32-amino acid-long segment within the unstructured 
domain. This ligand binding segment was shown to share 81–91% amino acid sequence 
Fig. E-4. Summary of interactions between B. burgdorferi and host cells. Top: In the starved Ixodes
tick, OspA promotes attachment of the spirochete to midgut epithelial cells by recognition of TROSPA 
on the epithelial cell surface. (Photo provided by the American Lyme Disease Foundation.) Bottom: In 
the north-eastern USA, the Peromyscus mouse is a natural host for B. burgdorferi. (Photo provided by 
S. Telford.) Attachment of the spirochete to mammalian cells can be mediated by DbpA or DbpB, 
which recognize decorin or GAGs, BBK32, which recognizes fibronectin or GAGs, or P66, which 
recognizes integrins. In addition, Bgp recognizes GAGs, however, an independent role for Bgp in cell 
attachment is not well established. 
TROSPA: tick receptor for OspA; GAG: glycosaminoglycans; Bgp: Borrelia GAG-binding protein; 
Fn: Fibronectin 
(Figure remodeled from Coburn et al., 2005) 
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identity with the homologous proteins encoded by bbk32 genes of B. burgdorferi s.s., B. 
garinii and B. afzelii (Probert et al., 2001). From the observation that gelatin could partially 
inhibit the binding of Fn to BBK32 and BBK32 could block the interaction of gelatin with 
Fn, it was speculated that the region of Fn bound by BBK32 overlapped with the Fn 
domain that binds gelatin and collagen (Probert et al., 1998).  
A former Ph.D student in our laboratory, Dr. Christiane Heimerl, found that the BBK32 of 
B. garinii isolate PHei possesses a stronger Fn-binding capacity than that of B. burgdorferi 
s.s B31 (C. Heimerl doctoral thesis, 2005) (Fig. E-5). In this section the molecular 
mechanism of the difference will be elucidated. 
 
Fig. E-5. BBK32 (PHei) exhibited a stronger Fn-binding capacity than BBK32 (B31) (Result of C. 
Heimerl doctoral thesis, 2005) 
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2.1. bbk32 gene fragment cloning and mutation construction 
Former study indicated that the Fn-binding activity of BBK32 was localized to a 32-amino 
acid-long segment within the N-terminal unstructured region (Probert et al., 2001). In this 
work, Fn-binding capacities of the N-terminal regions, and especially the 32-amino 
acid-long segments, of BBK32 proteins of PHei and B31 will be intensively investigated. 
Sequence alignment showed that 4 amino acids in this 32-amino acid-long segment were 
different between the two strains (Fig. E-6). Therefore, we suspected that the variation of 
the 4 amino acids might be responsible for the different Fn-binding capacities.  
Fig. E-6. Schematic showing the arrangement of Fn binding sites in BBK32 from B. burgdorferi
and BBK32 sequence comparison between B31 and PHei. The NTD/NTD-binding sites are shown in 
dark gray, and the GBD/GBD-binding sites are shown in light gray. The 32 amino acids responsible for 
the Fn binding activities of the proteins were framed. NTD: N-terminal domain; GBD: gelatin-binding 
domain. (The figure was partially modified from Rainbaud et al., 2005) 
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In this case, the whole BBK32 N-terminal region of both B31 and PHei was produced as 
both 3 independent segments (including the 32-amino acid-long segment, segments before 
and after the 32 amino acids) or as a whole. Deletion mutations without the 32 amino acids 
and site-specific point mutations were also included. Compared with BBK32 from B31, 
there is a six-amino acid-insertion (YYEDDY) in BBK32 from PHei, a whole BBK32 
N-terminal region of PHei including those additional 6 amino acids will be also prepared.  
2.1.1 PCR amplification of bbk32 fragments 
Based on comparison of the BBK32 N-terminal domains of PHei and B31, eight primers 
were designed. The locations of the eight primers P1 to P8 at the compared bbk32 
sequences of strains B31 and PHei were illustrated in Fig. E-7. By using the primer pairs 
listed in Table E-1, totally nine bbk32 gene segments with expected sizes were successfully 
generated by PCR amplification of genomic DNA isolated from B31 and PHei (Fig. E-8). 
Amplified PCR products were purified using a High Pure PCR product Kit and cloned into 
pGEM-T-easy vector and sequenced. Sequencing results showed that all the gene segments 
were successfully cloned. Detail sequence information were shown in appendix A and B. 
Table E-1. Primer pairs and their targeted bbk32 gene fragments for protein 
expression 
Isolate Primer pair Target gene fragment 
P1 and P4 bbk32 B31 ( 73-390) 
P6 and P7 bbk32 B31 (391-486) 
P8 and P2 bbk32 B31 (487-600) 
B. burgdorferi s.s. B31 
P1 and P2 bbk32 B31 (73-600) 
P1 and P4 bbk32 PHei (73-390) 
P6 and P7 bbk32 PHei (391-486) 
P8 and P2 bbk32 PHei (487-600) 
P1 and P2 bbk32 PHei (73-600) 
B. garinii PHei 
P1 and P3 bbk32 PHei (73-618) 
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P1 
P4 
P6 
P7 
P5 or P8 
P2 P3 
Fig. E-7. Locations of the 8 primers at the compared bbk32 gene fragments encoding its 
N-terminal regions of B. burgdorferi s.s. strain B31 and B. garinii strain PHei. Positions of the 
corresponding primers were framed and labelled with arrows.  
Fig. E-8. Agarose gel electrophoresis analysis of bbk32 PCR products 
PCR products were resolved through a 2.5% agarose gel. Lanes 1 to 9 were bbk32 B31 (73-390), bbk32 B31 
(391-486), bbk32 B31 (487-600), bbk32 B31 (73-600), bbk32 PHei (73-390), bbk32 PHei (391-486), bbk32 PHei (487-600), bbk32
PHei (73-600) and bbk32 PHei (73-618), respectively. Lane M was the DNA standard ladder.  
M  1  2  3  4  5  6  7  8  9
bp
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2.1.2 Construction of the bbk32 deletion mutations  
The strategy of construction of bbk32 deletion mutations was shown in Fig.E-9. Firstly, 
four gene segments of bbk32 from position 73 to 390 and from 487 to 600 were amplified 
from genomic DNA of strain B31 and PHei, respectively, using the two pairs of primers 
(P1 and P4; and, P5 and P2) in Table E-2. Amplified PCR products were purified using a 
High Pure PCR product Kit. After being digested with BsaHⅠ, the two segments were 
ligated together. The ligation product was PCR amplified with primer pairs P1 and P2. 
Sizes of the amplified PCR products and the ligation product (PCR amplified) were 
evaluated on an agarose gel as shown in Fig.E-10. The ligation product was cloned into 
pGEM-T-easy vector and sequenced. Sequencing results showed that nucleotides from 
position 391 to 486 were successfully deleted from the wild type genes. The two deletion 
mutations were designated bbk32PHeiΔ(391-486) and bbk32B31Δ(391-486), respectively. Their 
sequences were shown in appendix A and B. 
 
 
Fig. E-9. A schematic presentation of construction of bbk32 deletion mutations 
DNA fragments before and after nucleotide position 391 to 486 were PCR amplified and ligated to 
construct deletion mutation bbk32 PHeiΔ(391-486) and bbk32 B31Δ(391-486). 
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Table E-2. Primer pairs and targeted products for deletion mutation construction 
Isolate Primer pair Target gene fragment 
P1 and P4 bbk32 PHei (73-390) B. garinii PHei 
P5 and P2 bbk32 PHei (487-600) 
P1 and P4 bbk32 B31 (73-390) B. burgdorferi s.s. B31 
P5 and P2 bbk32 B31 (487-600)  
 
2.1.3 Construction of site-specific point mutations 
A strategy as shown in Fig.E-11 was used to construct the site-specific point mutations. 
Purified PCR products bbk32
 B31 (73-600) and bbk32 PHei (73-600) (Table E-1) were digested with 
FastDigest™ HaeⅢ and thus each of the DNA fragments was cleaved into two fragments 
with different lengths. The shorter digestion segment from B31 was ligated to the longer 
part of PHei, while the shorter one from PHei was joined to the longer one of B31. The 
ligation products were then followed a digestion of FastDigest™ Bst F51 and the generated 
DNA fragments were exchanged in the same way. To guarantee ligation of two fragments 
with their right direction (ligation happens at the ends with the same restriction site of the 
two fragments), ligated products were always PCR amplified with a primer pair (P1 and P2) 
after each ligation and the amplified PCR products were cloned into pGEM-T easy vector 
and confirmed by sequencing. Sequencing results showed that nucleotides from position 
390 to 486 were successfully exchanged between fragments bbk32 B31 (73-600) and bbk32 PHei 
(73-600) and thus they had the substituted nucleotide sequences of (391A, 433A, 439A, 450C 
and 463A), and (391C, 433G, 439C, 450T and 463C), respectively (see appendix A and B). 
The produced 2 mutations were named bbk32 B31 (73-389) PHei (390-486) B31 (487-600) and bbk32 PHei 
Fig. E-10. Agarose gel electrophoresis analysis of PCR products for construction of bbk32 deletion 
mutations and their ligation products. a. gene fragments from PHei and b. gene fragments from B31. 
M. DNA standard ladder; Lane 1. bbk32
 (73-390), lane 2.bbk32 (487-600) and lane 3. bbk32Δ(391-486). 
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(73-389) B31 (390-486) PHei (487-600), respectively. Hereafter, these two mutations in bbk32 were 
denoted as bbk32B31(73-600) mut and bbk32PHei (73-600) mut, respectively. The encoded 
corresponding polypeptides of the two mutations were designated BBK32B31 (25-200)mut and 
BBK32PHei (25-200)mut, respectively. The deduced amino acid sequence of the BBK32B31 (25-200) 
mut
 had substituted amino acids of lysine131, lysine145, threonine147 and isoleucine155, while 
that of BBK32PHei (25-200) mut had substituted ones of glutamine131, glutamic acid145, 
proline147 and leucine155 (Fig. E-13).  
 
2.2 Construction of expression plasmids 
The 13 bbk32 gene segments (Table E-3) generated in section 2.1 were cleaved from 
recombinant cloning plasmids, pGEM-T easy vector conceiving bbk32 segments, by BamH
Ⅰ and XhoⅠdouble digestion. Obtained bbk32 fragments were introduced into the BamH
Ⅰ/XhoⅠ restriction sites of the linearized expression vector pGEX by T4DNA ligase to 
construct expression plasmids pGEX-bbk32 (bbk32, any one of the 13 fragments) 
(Fig.E-12). Inserts of the constructed expression plasmids were confirmed by sequencing. 
Results showed that all the 13 bbk32 fragments were successfully inserted into the vectors. 
The deduced amino acid sequences of 13 bbk32 fragments were shown in Fig.E-13.  
Fig. E-11. A schematic presentation of construction of bbk32 site-specific point mutations 
Nucleotides from position 390 to 486 of wild type fragments bbk32B31 (73-600) and bbk32PHei (73-600) were 
exchanged between the two fragments by restriction enzyme treatment and ligation to produce gene 
segments bbk32B31 (73-600) mut and bbk32PHei (73-600) mut, respectively.  
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Table E-3. bbk32 gene fragments and their corresponding polypeptides 
Gene segments Polypeptide names Predicted MW (kDa)* 
bbk32 B31 (73-600) BBK32 B31 (25-200) 47 
bbk32
 B31 (73-600) 
mut 
 BBK32 B31 (25-200) mut 47 
bbk32 B31Δ(391-486) BBK32 B31Δ(131-162) 43 
bbk32 B31 (73-390) BBK32 B31 (25-130) 39 
bbk32 B31 (391-486) BBK32 B31 (131-162) 30 
bbk32 B31 (487-600) BBK32 B31 (163-200) 31 
bbk32 PHei (73-618) BBK32 PHei (25-206) 47 
bbk32 PHei (73-600) BBK32 PHei (25-200) 46 
bbk32 PHei (73-600) mut BBK32 PHei (25-200) mut 46 
bbk32 PHeiΔ(391-486) BBK32 PHeiΔ(131-162) 43 
bbk32 PHei (73-390) BBK32 PHei (25-130) 39 
bbk32 PHei (391-486) BBK32 PHei (131-162) 20 
bbk32 PHei (487-600) BBK32 PHei (163-200) 31 
* Molecular masses here referred to those of GST-BBK32 fusion proteins, the vector expressing GST 
protein’s MW 26kDa was added to MWs for every polypeptides. 
Fig. E-12. A scheme of introduction of bbk32 gene fragments into the restriction site of the 
linearized pGEX vector. The red bar indicates any one of the 13 bbk32 fragments. 
bbk32 fragment 
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2.3 Protein expression in E. coli and detection  
The constructed expression plasmids, pGEX inserted by bbk32 fragments, were 
transformed into BL21(DE3)pLysS competent cells and protein expression was then 
induced with IPTG. E. coli expressing BBK32 recombinant polypeptides were lysed and 
Fig. E-13. Comparison of the deduced amino acid sequences of BBK32 polypeptides. 
Protein fragments of the wild type BBK32 from both B31 and PHei and the generated mutations were 
compared using the ClustalV method in MegAlign component of the Lasergene software package for 
Windows (DNASTAR, Madison, WI). 
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analyzed by SDS-PAGE electrophoresis. Results showed that all the recombinant proteins 
fused with GST were successfully expressed with their expected sizes. A control protein, a 
28-kDa GST, was also produced from the expression vector, following induction with 
IPTG (Fig. E-14, top panel).  
To confirm their borrelial origin of the observed recombinant proteins in SDS-PAGE gels, 
lysate of recombinant E. coli expressing different protein fragments of BBK32 N-terminal 
regions of strain B31 and PHei were transferred to NC membranes for Western blot 
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Fig. E-14. SDS-PAGE and Western blot analysis of BBK32-GST fusion proteins 
Recombinant proteins were separated by SDS-PAGE and resolved proteins were either viewed directly by 
staining the gel with Coomassie brilliant blue or transferred to Nitrocellulose (NC) membrane for Western 
blot analysis. The membranes were immunoblotted with the same secondary antibody, swine anti-rabbit 
IgG-HRP conjugate. Prior to this, two membranes were incubated with rabbit anti-BBK32B31 polyclonal 
serum (1:750 diluted), while the other two were incubated with normal rabbit serum as negative controls. 
All the proteins were fused with GST and protein bands in (SDS-PAGE) were marked with arrows (◄). 
M was the molecular weight marker. 
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analysis. Results showed that except BBK32PHei (131-162), all the other BBK32 fragments 
were recognized by the rabbit anti-BBK32(B31) polyclonal serum, while the control protein 
GST was not (Fig. E-14, middle panel). Serum collected from a normal rabbit did not 
recognize any band on the blots (Fig. E-14, bottom panel). Some minor immunoreactive 
bands of lower MW than the dominant bands probably were degradation products of 
BBK32. 
2.4 Qualitative Fn-binding analysis 
So far 13 polypeptides representing different parts of the N- terminal regions and some 
corresponding mutations as well of BBK32 proteins were produced (Table E-3, Fig. F-14). 
Fig. E-15 illustrated the basic structures of all those prepared polypeptides.  
 
Fig. E-15. Illustration of basic structures of the 13 BBK32 polypeptides.: 
Position of amino acid residues 
In strain B31:   position 25-130;    position 131-162;    position 163-200. 
In strain PHei:   position 25-130;    position 131-162;    position 163-200;    position 201-206. 
GST  
K131, K145, T147 and I155.      
Q131, E145, P147 and L155. 
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To evaluate whether those polypeptides exhibiting Fn-binding capacities or not, qualitative 
binding analysis was carried out with non-purified recombinant proteins in a 
Western-ligand blot-based binding assay. Results in Fig. E-16 showed that the 32 amino 
acids from position 131 to 162 of BBK32 were almost responsible for the full Fn-binding 
capacities of the proteins, while amino acids before and after this region had no or quite 
weak binding capacities. This was further proved by the weak Fn-binding capacities of the 
two deletion mutations BBK32B31Δ(131-162) and BBK32PHeiΔ(131-162) , which did not contain 
the 32 amino acids in their middle parts. Results also showed that both the site-specific 
point mutations and the wild type N-terminal regions of BBK32 had quite strong 
Fn-binding capacities. Since all the recombinant proteins were fused with GST, Fn-binding 
capacity of GST protein was also examined. Results indicated that GST protein had no 
binding capacity to Fn. This suggested the BBK32 peptide segments were responsible for 
the whole Fn-binding capacities in the GST-BBK32 fusion proteins. Non-specific reactions 
might be caused by overloading or degradation of proteins. 
 
Fig. E-16. Western-ligand blot based fibronectin-binding assay of non-purified BBK32 proteins 
Recombinant proteins were separated by SDS-PAGE and transferred to NC membranes. The
membranes were incubated first with human fibronectin, then with polyclonal rabbit anti-human 
fibronectin, and finally with polyclonal swine anti-rabbit IgG-HRP conjugate. All the proteins were 
fused with GST. M was the molecular weight marker (kDa). 
kDa
117
85
48
34
26
M
 
B
B
K
32
B3
1 
(25
-
13
0) 
B
B
K
32
B3
1 
(13
1-
16
2) 
B
B
K
32
B3
1 
(16
3-
20
0) 
B
B
K
32
B3
1Δ
(13
1-
16
2) 
B
B
K
32
B3
1 
(25
-
20
0) 
m
u
t  
B
B
K
32
B3
1 
(25
-
20
0) 
G
ST
 
kDa
117
85
48
34
26
 
M
 
B
B
K
32
PH
ei
 
(25
-
13
0) 
B
B
K
32
PH
ei
 
(13
1-
16
2) 
B
B
K
32
PH
ei
 
(16
3-
20
0) 
B
B
K
32
PH
ei
Δ
(13
1-
16
2) 
B
B
K
32
PH
ei
 
(25
-
20
0) 
m
u
t 
B
B
K
32
PH
ei
 
(25
-
20
0) 
B
B
K
32
PH
ei
 
(25
-
20
6) 
G
ST
 
RESULTS 
 68
2.5 Purification of the seven polypeptides exhibiting strong 
Fn-binding capacity 
For further quantitative analysis of the Fn-binding capacities of BBK32 polypeptides, the 
seven GST fusion proteins showing strong Fn-binding capacities were purified with 
Glutathione Sepharose 4 Fast Flow beads. Protein concentrations were determined by the 
Bradford method (Bradford, 1976) using the standard curve prepared by application of 
BSA as a protein standard (Fig. E-17). The final concentration of each purified protein was 
brought to 100 µg/ml either by dilution with PBS or concentrated using Vivaspin 
concentrators following the manufacturer’s instruction. The purity of the purified proteins 
was monitored by SDS-PAGE and Western blot. Results indicated 6 out of the 7 BBK32 
polypeptides could be recognized by rabbit anti-BBK32B31 polyclonal serum, while rabbit 
anti-E. coli serum did not detect any protein bands on the blot. Although BBK32 PHei (131-162) 
could not be recognized by anti-BBK32B31 polyclonal serum, the presence of a single band 
only on the SDS-PAGE gel and non-reactivity with anti-E. coli polyclonal serum argued 
for successful purification of the respective antigen (Fig. E-18). Taken together, 7 proteins 
were regarded as pure enough for further investigations: BBK32 PHei (131-162), BBK32 B31 
(131-162), BBK32 PHei (25-200) mut, BBK32 B31 (25-200) mut, BBK32 PHei (25-200), BBK32 B31 (25-200) 
and BBK32 PHei (25-206), respectively. 
Fig. E-17. Standard curve for the Bio-Rad Protein Microassay (1-12 µg/ml) prepared from bovine 
serum albumin. 
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2.6 Quantitative Fn-binding assay 
To quantitatively compare the Fn-binding capacities of BBK32 from strains B31 and PHei, 
ELISA-based binding tests were performed using the seven purified BBK32 polypeptides. 
Microtitre plates were coated with 0.01 or 0.05 µg/well of each of the purified recombinant 
proteins overnight. Immobilized BBK32 proteins on the plates were incubated with 
0.1µg/ml human Fn to evaluate their Fn-binding capacities. Results (Fig. E-19, panel A) 
showed that BBK32 PHei (25-200) had a stronger Fn-binding capacity than BBK32 B31 (25-200) 
(P<0.05 in Student’s t-test). Further, in the case of the two 32-amino acid long-segments, 
Fig. E-18. SDS-PAGE and western blot analysis of the 7 purified BBK32-GST fusion proteins 
Purified proteins were separated by SDS-PAGE and then stained with Coomassie brilliant blue or 
transferred to NC membranes. The membranes were incubated with the same secondary antibody, 
swine anti-rabbit IgG-HRP conjugate. Prior to this, membrane in the middle was incubated with rabbit 
anti-BBK32B31 polyclonal antiserum, while membrane at bottom was incubated with rabbit anti-E. coli
polyclonal antiserum. All the proteins were fused with GST. M was the molecular weight marker. 
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BBK32PHei (131-162) and BBK32B31 (131-162), the former showed stronger capability to attach to 
Fn than the latter (P<0.05 in Student’s t-test). Sequence alignment showed that 4 amino 
acids were different between the two 32-amino acid long-segments. Obviously, the 
variation of the 4 residues could be responsible for the difference in the Fn-binding 
capacities. We speculated that the higher Fn-binding capacity of the whole BBK32 
N-terminal region of strain PHei might also be caused by the variation of the 4 amino acids. 
To prove our hypothesis, two mutations BBK32PHei (25-200) mut (Q131, E145, P147 and L155) and 
Fig. E-19. Binding of human fibronectin to immobilized BBK32 polypeptides.  
Ninety-six-well plates were coated with BBK32 polypeptides and subsequently incubated with human 
fibronectin to determine the capacity of these proteins adhere to fibronectin. The value shown indicated 
the mean of three binding assays per peptide tested and the errors bars represent the standard deviation 
observed. A. Microtitre plates were coated with 0.01 or 0.05 µg/well of BBK32 polypeptides and 
subsequently incubated with 0.1µg/ml human fibronectin. B. Microtitre plates were coated with 0.05 
µg/well of BBK32 polypeptides and subsequently incubated with 0.1 or 0.2 µg/ml human fibronectin. 
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BBK32B31 (25-200) mut (K131, K145, T147 and I155) were then constructed by exchanging all the 4 
amino acids between the whole N-terminal regions of BBK32s from PHei and B31. After 
substitution of the 4 amino acids, Fn-binding capacity of the constructed mutant BBK32PHei 
(25-200)
mut decreased greatly compared with its wild type BBK32PHei (25-200) (P<0.05) and even 
was the same as that of BBK32B31(25-200) (P>0.05). On the contrary, Fn-binding capacity of 
BBK32B31 (25-200) mut was increased to the same intensity as that of BBK32PHei (25-200) 
(P>0.05), which was much stronger than that of its wild type BBK32B31 (25-200). In addition, 
compared with BBK32 from B31, there is a 6 amino acid insertion (YYEDDY, from 
position 201 to 206) in BBK32 from isolate PHei, but these 6 amino acids did not influence 
the Fn-binding capacity because BBK32PHei (25-200) and BBK32PHei (25-206) showed similar 
Fn-binding capacity (P>0.05).  
In another trail, microtitre plates coated with 0.05 µg/well each of the 7 purified proteins 
were incubated with 0.1 or 0.2 µg/ml human Fn. Likewise, similar results as above were 
again obtained (Fig. E-19, panel B). 
2.7 Inhibition of the BBK32-Fn interaction with ligands 
Fn contains distinct domains that interact with heparin, collagen (gelatin), intergrins and 
other plasma and tissue components (Proctor, 1987; Pankov and Yamada, 2002; Owens 
and Baralle, 1986; Mardon and Grant, 1994; Matsuka et al., 1994; Coburn et al., 2005). 
One study indicated that the region of Fn bound by BBK32 overlapped with the Fn domain 
that binds gelatin and collagen (Probert et al., 1998). A former study also demonstrated the 
32-residue peptide (from position 131 to 162 in the N terminus of BBK32), which had been 
mapped to be the Fn-binding region of the protein, shared sequence homology to the 
upstream Fn-binding region of an Fn-binding protein (FnBP) (SfbI) from Streptococcus 
pyogenes (Probert et al. 2001). This region of SfbI had been shown to bind to the 
gelatin-binding domain (GBD) of Fn (Talay et al., 2000). Moreover, it has been shown that, 
like FnBPs from other Gram-positive pathogens Staphylococcus aureus and S. pyogenes, 
the unstructured N-terminus of BBK32 undergoes a significant conformational change 
upon binding to the F1 module in the N-terminal domain (NTD) of Fn with an increase in
β-sheet content in the complex (Kim et al., 2005; Raibaud et al., 2005). The observation 
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suggests that BBK32 could interact with the NTD of Fn in a similar manner to that of the 
FnBPs of S. aureus and S. pyogenes. To ascertain the region of Fn that interacts with 
BBK32s, we attempted to block specific binding sites using some known ligands of Fn. 
2.7.1 Western blot-based inhibition test 
Samples of purified BBK32 proteins (0.6µg/lane) were resolved by SDS-PAGE and 
transferred to NC membranes for Fn-binding assay. As shown in the upper panel in Fig. 
E-20, all the purified BBK32 polypeptides exhibited Fn-binding capacities. Again we found 
BBK32PHei (131-162) had a stronger Fn-binding capacity than BBK32B31 (131-162). In the lower 
panel, prior to incubation with human Fn, blot carrying BBK32 proteins was incubated 
Fig. E-20. Western blot based Fn-binding assay of purified BBK32-GST fusion proteins 
Recombinant proteins were separated by SDS-PAGE and transferred to NC membranes. Successive 
incubations of the blots were carried out in human fibronectin, polyclonal rabbit anti-human 
fibronectin, and polyclonal swine anti-rabbit IgG-HRP conjugate. Prior to reaction with human 
fibronectin, membrane in the bottom panel was incubation with 5mg/ml gelatin. All the proteins 
were fused with GST. M was the molecular weight marker. 
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with 5mg/ml gelatin. Result showed that the Fn-binding capacity of BBK32B31 (131-162) could 
be inhibited completely by 5 mg/ml gelatin, and gelatin could also weaken the Fn-binding 
capacities of BBK32B31(25-200) and BBK32PHei (25-200)mut as well. The minor bands migrated 
faster than the predicted BBK32 fragments did, suggesting that degradation of 
corresponding BBK32 polypeptides might take place (Fig.E-20, lower panel).  
2.7.2 Line assay-based inhibition test 
Line assay-based binding tests were developed to evaluate inhibition of BBK32 attachment 
to Fn. Prior to incubation with human Fn, the bound proteins on the strips were incubated 
with increasing concentrations of known Fn ligands collagen and gelatin, or with decorin 
and BSA as controls. Results showed that with the increasing concentrations of collagen 
and gelatin, continuous decreases in the Fn-binding capacity of BBK32B31(131-162) was 
observed (Fig. E-21). This suggested both collagen and gelatin could inhibit the Fn-binding 
capacity of BBK32B31(131-162). While neither BSA nor decorin could affect the attachment of 
BBK32B31 (131-162) to Fn. 
BBK32 PHei (131-162) 
BBK32 B31 (131-162) 
BBK32 PHei (25-200) mut 
BBK32 B31 (25-200) mut 
BBK32 PHei (25-200) 
BBK32 B31 (25-200) 
BBK32 PHei (25-206) 
1  2  3  4  5 1  2  3  4  5 1  2  3  4  5 1  2  3  4
Collagen Gelatin BSA Decorin 
Fig. E-21. Effect of ligand addition on the interaction of BBK32 polypeptides with fibronectin. 
Strips with same amount of BBK32 recombinant proteins at different positions were prepared as 
described in Materials and methods. Successive incubations of the strips were carried out in human Fn, 
polyclonal rabbit anti-human Fn, and polyclonal swine anti-rabbit IgG-HRP conjugate. Prior to 
incubation with human Fn, proteins on the blots were incubated with increasing concentrations of 
collagen, gelatin, BSA or Decorin. The concentrations of the 4 ligands from strip 1 to 5 in each group 
were 1, 5, 10, 50 and 100 µg/ml. 
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2.7.3 ELISA-based inhibition test 
To evaluate the inhibition impact caused by gelatin and collagen on the interaction between 
BBK32 and Fn in a quantitative manner, an ELISA-based inhibition assay was carried out. 
Human Fn was first incubated with diluent only or either gelatin, collagen or BSA before 
incubation with the immobilized BBK32 polypeptides on the microtitre plates. As shown in 
Fig. E-22 (panels A and B) both gelatin and collagen could inhibit the attachment of Fn to 
most of the BBK32 polypeptides in a dose dependent manner (P<0.05) (except 
BBK32B31[131-162] and BBK32B31 [25-200] mut). Since Fn-binding capacity of BBK32B31 (131-162) 
was not visible at this low concentration (0.05µg/well), inhibition impact caused by gelatin 
or collagen on it could not be observed. In the case of BBK32B31(25-200) mut, the addition of 
50 µg/ml of gelatin could cause a minor decrease in its Fn-binding capacity (P<0.05), while 
collagen could not inhibit the Fn-binding capacity of BBK32B31(25-200)mut. Moreover, 
addition of gelatin and collagen caused a greater inhibition impact on BBK32B31(25-200) than 
on BBK32PHei (25-200) and BBK32PHei (25-206) (Table E-4). The mutation of the 4 amino acids 
in BBK32PHei (25-200) greatly increased the inhibition effect of both gelatin and collagen on 
BBK32PHei (25-200) mut binding to Fn. On the contrary, after the mutation of the 4 amino acids 
in BBK32B31(25-200), the inhibition impact caused by gelatin and collagen on BBK32B31(25-200) 
mut
 was reduced dramatically or even no inhibition was observed. These results indicated 
that the sites of BBK32 interaction overlapped with the gelatin or collagen binding domains 
of Fn. However, BBK32 from isolate B31 might possess a higher percentage of overlap 
with the gelatin or collagen binding domain of Fn than protein from isolate PHei had. In 
contrast, preincubation of Fn with BSA had no effect on BBK32 polypeptides/ Fn binding 
activities (Fig. E-22, panel C). 
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Fig. E-22. Effect of preincubation of ligand and fibronectin on BBK32-fibronectin interaction.  
Ninety-six-well plates were coated with 0.05µg BBK32 polypeptides per well. Before being used to probe 
BBK32 proteins in the plates, human Fn was incubated with either diluent or different concentrations of 
ligands. Ligand in panel A, B and C were collagen, gelatin and BSA, respectively. The value shown 
indicated the mean of three binding assays per peptide tested and the errors bars represent the standard 
deviation observed. Asterisks indicated that the ligand could significantly inhibit the interaction of 
BBK32 peptide and Fn (P<0.05).  
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Table E-4. Effect of preincubation of ligand and Fn on the interaction of BBK32 
polypeptides and Fn.  
Percent fibronectin binding activity (%) a Protein 
10µg/ml  
BSA 
50µg/ml  
BSA 
10µg/ml 
gelatin 
50µg/ml 
gelatin 
10µg/ml 
collagen 
50µg/ml 
collagen 
BBK32PHei (131-162) 99 105 18 7 43 30 
BBK32B31 (131-162) b — — — — — — 
BBK32PHei (25-200) mut 99 91 21 10 44 28 
BBK32B31 (25-200) mut 108 108 92 76 97 102 
BBK32PHei (25-200) 105 103 77 56 83 80 
BBK32B31 (25-200) 101 91 31 10 53 32 
BBK32PHei (25-206) 110 107 89 70 86 74 
a. (average absorbance of wells receiving ligand/average absorbance of wells receiving diluent)×100. 
b. Since Fn-binding capacity of BBK32B31 (131-162) was not visible at this low concentration (0.05µg/well), 
inhibition impact caused by ligands could not be observed. 
3. Application of recombinant BBK32 in serodiagnosis of Lyme 
borreliosis  
Due to limitations in direct detection of B. burgdorferi s.l. in clinical specimens, antibody 
detection methods have been the main laboratory modality used to support a clinical 
diagnosis of Lyme borreliosis. Serological diagnosis should follow the principle of a 
two-step procedure: a sensitive enzyme-linked immunosorbent analysis as the first step, 
followed by immunoblot (IgM and IgG) if reactive (Wilske et al., 2007a). An in-house 
recombinant immunoblot previously developed by Wilske and her colleagues have been 
improved significantly by the addition of several other antigens such as VlsE and DbpA 
(Wilske et al., 1999; Schulte-Spechtel et al., 2003, 2006; Goettner et al., 2005). As the 
improvement of immunoblot for serological test is desirable, we checked the suitability of 
BBK32 proteins as antigens. 
Several studies suggested that BBK32 might be a good antigen in serological diagnosis of 
Lyme borreliosis (Heikkilä et al., 2002; Lahdenne et al., 2003; Panelius et al., 2003; 
Lahdenne et al., 2006). One investigation also indicated that BBK32 fragments might 
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improve the early IgG serology of Lyme borreliosis compared to the BBK32 whole protein 
(Lahdenne et al., 2006). Moreover, In Europe and Asia, the development of a uniform 
approach for the serological evaluation of Lyme borreliosis is always complicated by the 
prevalence of organisms from the three or more genospecies of B. burgdorferi s.l. and by 
the antigenic diversity due to variations in the sequences and expression of immunogenic 
proteins in these different Borrelia species (Wang et al., 1999b; Baranton et al., 1992; 
Robertson et al., 2000; Roessler et al., 1997; Goettner et al., 2005; Schulte-Spechtel et al., 
2003; Schulte-Spechtel et al., 2006).  
We investigated here the implication of recombinant BBK32s in line assay for serological 
diagnosis of Lyme borreliosis. In order to cover all the frequent pathogenic Borrelia species 
that cause human Lyme borreliosis, we prepared 8 BBK32 homogoues from different 
strains of the three pathogenic borrelial species, B. burgdorferi s.s., B. afzelii, and B. garinii. 
The respective variant rBBK32s were tested for use in Lyme borreliosis serology by using 
serum samples from patients suffering from the disease at early- and late-stage.  
3.1 Cloning of bbk32 gene fragments 
In order to produce recombinant BBK32 proteins as both whole and partial as antigens for 
serological diagnosis of Lyme borreliosis, four bbk32 gene segments were amplified from 
genomic DNA isolated from strain B31, PBi and PKo by using the primer pairs in Table 
E-5. Agarose electrophoresis analysis showed that 3 of the amplified PCR products were 
with a size of around 580 bp, and the other one was about 1000bp length (Fig. E-23). The 
amplified PCR products were ligated into pGEM-T-easy vector and sequenced. Sequencing 
results showed that the four bbk32 gene segments were successfully cloned. Since the 
shorter bbk32 segment (around 580 bp) was only encoding the N-terminal part of the whole 
BBK32, the 3 short bbk32 segments from strain B31, PBi and PKo were designated 
bbk32B31 partial, bbk32PBi partial and bbk32PKo partial, respectively. And their encoding proteins 
were named as BBK32B31 partial, BBK32PBi partial and BBK32PKo partial, correspondingly. The 
1000bp-length bbk32 gene segment amplified from strain PKo was given a name of 
bbk32PKo whole and BBK32PKo whole for its encoding protein. The cloned nucleotide sequence 
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and its deduced amino acid sequence bbk32 PKo whole were shown in Fig. E-24.  
 
Fig. E-23. Amplified PCR products of bbk32 gene partial and whole fragments 
PCR products were electrophoresed through a 2.5% agarose gel. Lanes 1 to 4 were bbk32 B31 partial, 
bbk32
 PBi partial, bbk32 PKo partial and bbk32 PKo whole, respectively. M was the DNA standard ladder.  
bp
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900
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700
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M  1  2  3  4
1000 bp 
580 bp 
Fig. E-24. Nucleotide sequence of the cloned bbk32 PKo whole and its deduced amino acid 
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Table E-5. Primer pairs and their targeted bbk32 fragments for protein expression 
Isolate Primer pair Target gene fragment 
B. burgdorferi s.s. B31 Forward P1 and Reverse P1 bbk32 B31 partial 
B. garinii PBi Forward P1 and Reverse P1 bbk32
 PBi partial 
B. afzelii PKo Forward P1 and Reverse P1 bbk32 PKo partial 
 Forward P1 and Reverse P2 bbk32 PKo whole 
3.2 Sequence comparative analysis  
The 3 shorter gene fragments bbk32B31 partial, bbk32PBi partial and bbk32PKo partial and their 
deduced amino acid sequences were aligned using the Clustal V method in MegAlign 
component of DNASTAR. At the nucleotide level, identities shared by the three shorter 
bbk32 segments ranged from 78% to 89%, and at their amino acid level the identities were 
between 65% and 81%. Comparison of the three partial sequences was shown in Fig. E-25. 
Obviously, BBK32 has a much higher amino acid sequence heterogencity compared to the 
DNA sequence heterogeneity. 
To further confirm this, open reading frames (ORFs) of 16 bbk32 sequences from the 
GenBank database were aligned and a sequence homology tree (DNA tree) was created 
with the DNAMAN software. Identity shared by bbk32 DNA sequences was relatively high 
ranging from 84 to 100%. In the tree, the selected bbk32 DNA sequences were divided into 
two big groups (group I and group II). Group I comprised all the B. afzelii strains and 
bbk32 sequences in this group were highly conserved (showing 100% identity). While all 
the strains from B. garinii and B. burfdorferi s.s. were clusterd into group II. As a whole, 
bbk32 sequences in group II were also quite homologous, with the exception of PBi, which 
showing more variation (Fig. E-26). Another tree (AA tree) was constructed by alignment 
of the BBK32 amino acid sequences derived by the 16 ORFs with the same software. Like 
their corresponding DNA sequences, again the BBK32 amnio acid sequences were 
clustered into two big groups. However, identities shared by the amino acid sequences were 
lower compared to their DNA sequences (Fig. E-26). Comparison of the amino acid 
sequence homology tree with the DNA sequence identity revealed a decrease of minimal 
BBK32 sequence identities from 84 to 71% from the DNA to the amino acid level. 
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Fig. E-25. Sequence comparison of bbk32 partial gene fragments of strains B31, PBi and PKo and 
their deduced amino acid sequences. 
The cloned bbk32 partial gene fragments bbk32B31 partial, bbk32PBi partial and bbk32PKo partial (in panel A) and 
their encoding amino acid sequences BBK32B31 partial, BBK32PBi partial and BBK32PKo partial (in panel B) were 
aligned using the Clustal V method in MegAlign component of DNASTAR.  
The deduced amino acid sequences of BBK32 , BBK32  and BBK32  were aligned 
A 
B 
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3.3 Construction of expression plasmids and protein expression 
Recombinant cloning plasmids, pGEM-T easy vector inserted by bbk32B31 partial, bbk32PBi 
partial, bbk32PKo partial or bbk32PKo whole, were cleaved by BamHⅠand XhoⅠdouble digestion. 
Released bbk32 gene fragments were subcloned into the BamHⅠ/XhoⅠrestriction sites of 
the linearized expression vector pGEX by T4DNA ligase. The constructed expression 
plasmids, pGEX inserted by bbk32 fragments, were transformed into BL21(DE3)pLysS 
competent cells and protein expression was then induced with IPTG. Expression products 
were examined by SDS-PAGE electrophoresis. Results showed that the 4 GST fusion 
proteins were successfully expressed with their expected sizes. GST protein was also 
produced as a control (Fig. E-27).  
group I 
group II 
AA tree 
Fig. E-26. Sequence homology trees of BBK32 sequences of Borrelia burgdorferi s.l. strains.  
Both DNA sequences and their deduced amino acid (AA) sequences of BBK32s from a variety of 
borrelial strains were aligned with the DNAMAN software and two homology trees (DNA tree and AA 
tree) were created. In the figures: B.b, Borrelia bugdorferi s.s.; B. g. Borrelia garinii; and B. a, Borrelia 
afzelii. GenBank accession numbers of involved bbk32 genes see Table D-4.  
group I 
group II 
DNA tree 
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3.4 Purification of recombinant proteins 
At first, the four recombinant proteins BBK32B31partial, BBK32PBi partial, BBK32PKo parital and 
BBK32PKo whole were purified with Glutathione Sepharose 4 Fast Flow beads. However, 
after purification, they were still contaminated by E. coli proteins. The 4 proteins together 
with some other partially purified BBK32 proteins (whole BBK32 from strains B31, PKa2, 
PHei and TN) produced before (Heimerl, 2005) were again purified with a Polyacrylamide 
gel. After the second round of purification, a single band for each purifed protein was 
observed on the SDS-PAGE gel (Fig. E-28, a and c). In Western blot analysis, before 
purification, all the protein samples had cross-reactions with rabbit anti-E. coli polyclonal 
antibody, while all those non-specific bands disappeared after this purification (Fig. E-28, b 
and d). All the 8 purified BBK32 homologues could be recognized by rabbit anti-BBK32B31 
polyclonal antibody in Western blot analysis (Fig. E-29) 
Fig. E-27. SDS-PAGE analysis of BBK32-GST fusion proteins 
Recombinant proteins were separated by SDS-PAGE and stained with Coomassie brilliant blue. Lanes 
1, 3, 5 and 7 were overnight cultures without induction with IPTG; lanes 2, 4, 6 and 8 were 
IPTG-induced proteins BBK32B31 partial, BBK32PBi partial, BBK32PKo partial and BBK32PKo whole, 
respectively; and lane 9 was the GST control. All the proteins were fused with GST and the target 
protein bands were marked with arrows (◄). M was the molecular weight marker. 
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Fig. E-28. Detection of BBK32 proteins after being purified with Polyacrylamide gel  
BBK32 proteins before and after purification were separated by SDS-PAGE and then stained with 
Coomassie brilliant blue (panel a and c) or transferred to a membrane (panels b and d). The two 
membranes were first incubated with rabbit anti-E. coli polyclonal antiserum, and then immunoblotted 
with the secondary antibody, swine anti-rabbit IgG-HRP conjugate. In panels a and b, lane 1, 3, 5 and 7 
were E. coli lysate expressing BBK32B31 partial, BBK32PBi partial, BBK32PKo partial and BBK32PKo whole
respectively; while lane 2, 4, 6 and 8 were purified corresponding proteins. In panel c and d, lane 1, 3, 5 
and 7 were partially purified recombinant BBK32 whole proteins originated from strains B31, PHei, 
PKa2 and TN; Lane 2, 4, 6 and 8 were purified BBK32 whole proteins from corresponding strains. M 
was the molecular weight marker. 
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Fig. E-29. SDS-PAGE and western blot analysis of the 8 purified BBK32 proteins 
Purified BBK32 proteins were separated by SDS-PAGE and then stained with Coomassie brilliant 
blue (panel a) or transferred to a membrane (panels b). The membrane was immunoblotted with rabbit 
anti-BBK32B31 polyclonal antiserum, and the bound first antibody was detected with swine anti-rabbit 
IgG-HRP conjugate. Lanes were labelled with corresponding strain designation from which BBK32
proteins were produced. –GST, the protein was fused with GST; His-tag: the protein was fused with a 
6-His tag. M was the molecular weight marker. 
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3.5 Application of BBK32 proteins in line assay 
Eight BBK32 homologues (both partial and whole as shown in Table E-6) from different 
borrelial stains were tested with a panel of 72 serum samples of Lyme borreliosis patients. 
Fig. E-30 exemplarily shows the reaction of sera from 8 patients with ACA with the 8 
BBK32s.  
Table E-6. BBK32 proteins from B. burgdorferi s.l. used in line assay 
Species Proteins 
B. burgdorferi s. s. BBK32
 B31 partail, GST fused 
BBK32B31 whole, His-tag fused 
BBK32PKa2 whole, His-tag fused 
B. garinii BBK32PBi partial, GST fused 
BBK32PHei whole, His-tag fused 
BBK32TN whole, His-tag fused 
B. afzelii BBK32PKo partail, GST fused 
 BBK32PKo whole, GST fused 
Results in Table E-7 showed 13 out of 24 (54.1%) sera from patients with EM, 6 out of 40 
(15%) sera from patients with NB, and 8 out of 8 (100%) sera from patients with ACA 
reacted positive with rBBK32 proteins from strains B31, PKa2, PHei, PBi and TN. No sera 
from patients with EM, only 1 out of 40 sera from patients with NB and 5 out of 8 sera 
from patients with ACA reacted positive with rBBK32 from strain PKo. No negative sera 
could react with the rBBK32 proteins. The results indicated rBBK32 from B. burgdorferi 
s.s. and B. garinii could be valuable antigens for diagnosis of Lyme borreliosis, especially 
in ACA. Notably, partial and whole rBBK32 proteins from B. burgdorferi s.s. shared the 
same sensitivity in the diagnosis of Lyme borreliosis, while whole BBK32 proteins from B. 
garinii exhibited a higher sensitivity than their corresponding partial ones. 
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Table E-7. Reactivity of human Lyme borreliosis sera with rBBK32s  
  No. (%) of positive sera (IgG)  
Group a No. of sera rBBK32 
B. burgdorferi s.s. and B. garinii 
rBBK32 
B. afzelii 
EM 24 13*(54.1) 0 (0.0) 
NB 40 6 (15) 1 (2.5) 
ACA 8 8 (100) 5 (62.5) 
All cases 72 27 (37.5)  6 (8.3) 
Controls 20 0 (0.0) 0 (0.0) 
a EM, erythema migrans (stage I) 
 NB, early neuroborreliosis (stage II) 
 ACA, acrodermatitis chronica atrophicans (stage III) 
* partially weak reactions 
 
BBK32 
B31 partial 
B31 whole 
PKa2 whole 
 
 
PBi partial 
PHei whole 
TN whole 
 
 
PKo partial 
PKo whole 
A  B
Fig. E-30. Reactivity of recombinant BBK32s from B. burgdorferi s.s. (B31 and PKa2), B. 
garinii (PBi, PHei and TN), and B. afzelii (PKo) using the line immunoblot. (A) Exemplary 
reactivity of negative sera (n=7, from healthy blood donors). (B) Exemplary reactivity of patient 
sera (n=8, from patients with ACA). 
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F. DISCUSSION 
1. The various locations of bbk32 on the borrelial genome 
B. burgdorferi conceives a segmented genome that includes a small, 900 kb linear 
chromosome and as many as 23 circular and linear plasmids, ranging in size from 5 kb to 
56 kb (Fraser et al., 1997; Stevenson et al., 1997; 1998; Casjens et al., 2000; Miller et al., 
2000). The gene bbk32 was sequenced from the 36kbp linear plasmid (lp36) of B31 (Fraser 
et al., 1997). Here we also localized bbk32 on lp36 of strains B. burgdorferi s.s. B31 and 
PKa2. However, the gene was localized no a 31kpb plasmid in strain N40 in this species. 
Moreover, our study showed that the location of bbk32 was quite various among different 
species and even differ between strains within one species. In strains of B. garinii, B. afzelii 
and B. spielmanii, bbk32 is carried by plasmids with sizes ranging from 23 kb to 28 kb (Fig. 
E-3). Our results here are consistent with that of Palmer’s in the aspect that genes carried 
by 36kbp linear plasmid in B31 are often found on 24-29kbp linear plasmids in other 
isolates (Palmer et al., 2000). 
The B. burgdorferi genome is unstable during in vitro passage and many of the plasmids 
can be lost during this process (Busch et al., 1997; Schwan et al., 1988; Norris et al., 1995; 
Xu et al., 1996; Xu et al., 2005; Purser and Norris, 2000; Labandeira-Rey and Skare, 2001; 
McDowell et al., 2001; Labandeira-Rey et al., 2003; Grimm et al., 2004; 2005; Lawrenz et 
al., 2004; Strother et al., 2005; Glöckner et al., 2006). Here gene bbk32 was not detected in 
some strains of the strain collection suggests loss of corresponding plasmids harboring the 
gene bbk32 during cultivation.  
Other reasons for lack of hybridization signal might be that bbk32 genes are ploymorph and 
cannot be detected with the DNA-probes derived from strains B31, PKo and PBi.  
2. Comparative analysis of the Fn-binding capacities of BBK32 
proteins  
For many bacterial pathogens, binding to host tissues is an essential step during 
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colonization and is typically mediated by adhesins, i.e., surface proteins that promote 
bacterial attachment to host cells (Boyle et al., 2003; Finlay et al., 1997; Joh et al., 1999; 
Menzies, 2003). To gain entry into the host through mucosal surfaces, bacterial pathogens 
express fimbrial and/or afimbrial adhesins that bind to various abundant sugar moieties of 
glycolipids and glycoproteins on epithelial cells. Mucosal colonization by pathogens often 
results in inflammation and tissue damage that exposes the underlying extracellular matrix. 
Binding to integrin and components of the extracellular matrix, such as Fn and collagen, by 
pathogens not only promotes bacterial colonization but also facilitates bacterial invasion 
into deeper tissues, which may lead to systemic dissemination (Cabello et al., 2007; 
Coburn et al., 2005).  
Fn is a large, dimeric glycoprotein that is produced by a broad range of cell types. It exists 
as a soluble molecule in body fluids such as blood plasma and as a splice-variant as 
insoluble cellular Fn of cell membranes and the extracellular matrix. Its two nearly 
identical subunits of 220-250 kDa are linked covalently near their carboxyl-termini by a 
pair of disulfide bonds. Each monomer is comprised of three different types of homologous 
repeating domains, termed Type I, II and III (Hynes, 1990). Fn contains 12 type I repeats, 
two type II repeats and 15-17 type III repeats. Through these functional domains, Fn can 
interact with a variety of macromolecules such as fibrin, heparin, collagen, and integrins as 
well. Many of these functional domains are also targeted by adhesins expressed by 
pathogenic microorganisms (Fig. F-1) (Proctor, 1987; Pankov and Yamada, 2002). 
Streptococcal fibronectin binding protein I (SfbI) and its allelic variant (F1) mediate 
adherence to and invasion of S. pyogenes into human epithelial cells by binding to the 
whole N-terminal fragment of Fn (includes the N-terminal fibrin binding domain of Fn, 
repeat I1-5, and the collagen-binding domain of Fn, repeat I6-9 and II1, 2) (Joh et al., 1998; 
Talay et al., 2000; Ozeri et al., 1996). The collagen-binding domain (repeat I6-9 and II1, 2) 
binds far more effectively to denatured collagen (gelatin) than to native collagen. Thus Fn 
interactions with collagens in general may be due to its binding to unfolded regions of the 
collagen triple helix (Pankov and Yamada, 2002).  
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Up to now, several adhesins expressed by Borrelia species that can bind Fn have been 
identified (Grab et al., 1998; Kopp et al., 1995; Probert et al., 1998; Schorey et al., 1996). 
BBK32, a 47-kDa lipoprotein, is a primary Fn-binding adhesins identified in B. burgdorferi 
(Probert et al., 1998). Overexpression of BBK32 protein in high-passage B. burgdorferi 
strain that lacks this protein enhances the organism’s binding to Fn, as well as to 
glycosaminoglycans (Fischer et al., 2006). Furthermore, inactivation of bbk32 gene in 
infectious strains of B. burgdorferi reduced spirochetal binding to Fn, as well as its 
infectivity in mice (Seshu et al., 2006), although the mutations had no apparent defect in 
tick vectors (Li et al., 2006). These findings suggested that BBK32 might run an important 
role in the adhesion and invasion activities of B. burgdorferi to its host tissues 
BBK32 consists of a C-terminal globular domain and an N-terminal region lacking 
well-defined secondary structure (Kim et al., 2004). In prior studies, the Fn-binding 
activity of BBK32 was localized to a 32-amino acid-long segment within the unstructured 
domain. This ligand-binding segment was relatively conserved among strains (Probert et al., 
2001). Previously, this research group found that BBK32 protein from strain PHei 
possessed a stronger Fn-binding capacity than that from B31 (C. Heimerl doctoral thesis, 
2005). In this study the molecular mechanism of this difference was clarified. Since it has 
already been described that the N-termianl region, and especially the 32-amino acid-long 
segment in this region is mainly responsible for the Fn-binding activity of BBK32 (Probert 
et al., 2001), Fn-binding capacities of the N-terminal region, and especially the 32-amino 
Fig. F-1. Domain structure of fibronectin (Fn).  
Fn consists of type I (rectangles), type II (ovals) and type III (circles) repeats. Sets of repeats constitute 
binding domains for fibrin, FN, collagen, cells and heparin, as indicated. The assembly domain and 
FN-binding sites are highlighted in orange. SS indicates the C-terminal systeines that form the dimer. 
(Figure remodeled from Wierzbicka-Patynowski and Schwarzbauer, 2003). 
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acid-long fragment from both strain PHei and B31 were intensively investigated in this 
thesis. By sequence comparison, four amino acids in this 32-amino acid-long segment were 
found different between the two strains (Fig. E-6). We speculated that the 4 different amino 
acids should be responsible for the different Fn-binding capacities. In this case, a variety of 
protein fragments including some mutated proteins (see Fig. E-15) were generated and their 
Fn-binding capacities were evaluated. In Western blot (Fig. E-14), 12 out of the 13 
produced BBK32 polypeptides could be recoginzed by rabbit anti-BBK32B31 polyclonal 
antibody, suggesting that the protein bands with expected sizes observed with Coomassie 
staining were in fact BBK32 protein fragments. The non-reactivity of BBK32PHei (131-162) 
with the rabbit immune serum might be due to the fact, that the antigen used to generate the 
polyclonal antibody in rabbit was from strain B31, while 4 out of the 32 amino acids of 
BBK32PHei (131-162) are different to the corresponding region of BBK32 from B31.  
At first, Fn-binding capacities of all the produced polypeptides were evaluated by using a 
Western blot-based Fn-binding assays. Just as reported by Probert and his colleagues 
(2001), we also found that the 32-amino acid-long segment (from position 131-162) was 
mainly responsible for the Fn-binding capacity of BBK32 proteins. Strikingly, amino acid 
residues proximal and distal from the 32-amino acid-long segment had quite weak or even 
no Fn-binding capacity. And this was further confirmed by the weak Fn-binding capacities 
of the two deletion mutations, which did not contain the 32 amino acids in their middle 
parts. The whole N-terminal regions of BBK32 from both strains and two other proteins 
containing the four substituted amino acids in the 32-amino acid-long region also exhibited 
strong Fn-binding capacities (Fig. E-16).  
To compare the Fn-binding capacities of those proteins quantitatively, seven purified 
BBK32 polypeptides were evaluated in an ELISA-based Fn-binding assay. Again, the 
32-amino acid-long segment from PHei showed a stronger Fn-binding capacity than the 
corresponding region from B31 (P<0.05). Furthermore, compared with its wild type protein 
BBK32PHei (25-200), Fn-binding capacity of BBK32PHei (25-200) mut decreased dramatically 
(P<0.05) to such an extent that there was no difference in the Fn-binding capacity between 
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BBK32PHei (25-200) mut and the wild type protein BBK32B31 (25-200) (P>0.05). While on the 
contrary, Fn-binding capacity of BBK32B31 (25-200) mut which containing the 4 substituted 
amino acids increased to as strong as that of the wild type BBK32PHei (25-200) (P<0.05) (Fig. 
E-19). All these data demonstrated that the replacement of the 4 amino acids motif in the 
32-amino acid-long segment of PHei greatly increased its attachment to Fn and this even 
led to the high affinity of the whole BBK32 protein to Fn. In addition, it must be 
emphasized that although the 32- amino acid-long segment in BBK32 plays a critical role 
in binding to Fn, it could not be responsible for the whole Fn-binding capacity of BBK32. 
On the one hand, although quite weak, protein segments before and after this 32-amino 
acid-long segment also can bind to Fn (Fig. E-16). On the other hand, whole N-terminal 
region of BBK32 exhibited a stronger Fn-binding capacity than the 32-amino acid-long 
segment in its middle part (P<0.05). 
Like Fn-binding proteins (FnBPs) from other Gram-positive pathogens such as S. aureus 
and S. pyogenes, binding of BBK32 to the F1 module in the N-teriminal domain (NTD) of 
host Fn converts the unstructured amino-terminus of BBK32 into a stable β-sheet 
structure (Kim et al., 2005; Raibaud et al., 2005; Joh et al., 1999; Menzies, 2003). The 
observation suggests that BBK32 could interact with the NTD of Fn in a similar manner to 
that of the FnBPs of S. aureus and S. pyogenes. Previous studies also demonstrated that the 
ligand-binding region of BBK32 (the 32 amino acids from position 131 to 162) shared 
sequence homology to the upstream Fn-binding region of an FnBP (SfbI) from S. pyogenes 
(Probert et al. 2001). This region of SfbI had been shown to specifically bind to the 
collagen-binding domain of Fn (Talay et al., 2000). From the observation that gelatin could 
partially inhibit the binding of Fn to BBK32 and BBK32 could block the interaction of 
gelatin and Fn, it was speculated that the collagen-binding domain of Fn might contain a 
binding site for BBK32 (Probert et al., 1998). To ascertain the region of Fn that interacts 
with BBK32 proteins, we attempted to block specific binding sites using some known 
ligands of Fn such as collagen and gelatin. 
In a Western blot-based binding assay, preincubation of gelatin with BBK32 proteins could 
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reduce the binding of Fn to the whole N-terminal region of BBK32 (B31) and especially 
the 32-amino acid-long segment of the strain (Fig.E-20). Further, in a line assay, with the 
increase of the concentration of gelatin or collagen, continuous decreases in the binding of 
Fn to the 32-amino acid-long segments (from both B31 and PHei) were observed (Fig. 
E-21). This suggests the entire N-terminal region of BBK32 from B31 also can bind to 
collagen/gelatin, and the collagen/gelatin binding region of the BBK32 should be in the 
32-amino acid-long segment. Once this region was occupied by collagen/gelatin, its 
capability of binding to Fn was highly inhibited. Thus we suggest that BBK32 from B. 
burgdorferi s.s. B31 should also be a collagen/gelatin binding protein. 
In an ELISA based inhibition test, preincubation of Fn with both gelatin and collagen could 
inhibit the attachment of Fn to wild BBK32 polypeptides of the two strains. However, 
gelatin and collagen caused a greater inhibition impact on BBK32 polypeptides from B31 
(Fig. E-22, Table E-4). This different inhibition effect was further confirmed in the two 
mutations, BBK32B31(25-200)mut and BBK32B31(25-200)mut. The mutation of the 4 amino acids in 
BBK32PHei (25-200) greatly increased the inhibition effects of both gelatin and collagen on 
BBK32PHei (25-200) mut binding to Fn. On the contrary, after the mutation of the 4 amino acids 
in BBK32B31(25-200), the inhibition impact caused by gelatin and collagen on 
BBK32B31(25-200)mut was reduced dramatically or even no inhibition was observed (Fig. E-22, 
Table E-4). These results indicated that BBK32 proteins mainly bind to the 
collagen-binding domain of Fn (repeat I6-9 and II1, 2). However, preincubation of Fn with 
gelatin or collagen could not thoroughly block the interaction between Fn and BBK32, this 
indicates that BBK32 might also partially bind to the N-terminal fibrin binding domain of 
Fn (repeat I1-5) in a similar manner to that of the FnBPs of S. aureus and S. pyogenes (Joh 
et al., 1998; Talay et al., 2000; Ozeri et al., 1996). Sequence homology shared by the 
32-amino acid-long segment of BBK32 and the upstream Fn-binding region of an FnBP 
(SfbI) from S. pyogenes also supports our hypothesis (Probert et al. 2001).  
Moreover, on the one hand, the higher affinity of the 32-amino acid-long segment from 
BBK32PHei to Fn might be difficult to be inhibited by collagen or gelatin. On the other hand, 
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BBK32 from isolate B31 might possess a higher percentage of overlap with the gelatin or 
collagen binding domain of Fn than protein from isolate PHei. In addition, since other 
regions rather than the 32-amino acid-long segment of BBK32 could also bind to other 
domains of Fn (presumably the repeat I1-5) and/or because of the high concentration of 
proteins on the blot in the immunoblot-based inhibition assays, the inhibition impact of 
gelatin and collagen on other polypeptides were not visible (Fig. E-20; E-21). With an 
amount of 0.05µg BBK32B31 (131-162) per well in the microtiter plate, the polypeptide 
exhibited a quite weak Fn-binding capacity, so the inhibition impact caused by gelatin or 
collagen on it could not be observed (Fig. E-19, E-22, Table E-4).  
Our results also suggested compared to collagen, gelatin exhibited a higher inhibition effect 
on the interaction of BBK32 and Fn, this is consistent with the fact that the 
collagen-binding domain (repeat I6-9 and II1, 2) binds far more effectively to denatured 
collagen (gelatin) than to native collagen (Pankov and Yamada, 2002). 
From a strategy point of view, by using restriction enzyme digestion and T4DNA ligation, 
the construction of the four mutations was largely simplified compared with traditional 
PCR directed mutation. For construction of the two deletion mutations, bbk32PHeiΔ(391-486) 
and bbk32B31Δ(391-486), a site-directed silent mutation was carried out in order to create 
BsaHⅠ site (GACGCC) at the 3’-end of bbk32(73-390), where the threonine codon 
(nucleotide 388-390) was changed from ACT to ACG. And the same restriction enzyme site 
was also created at the 5’-end of the gene fragment bbk32(487-600). After digestion with BsaH
Ⅰ, the two gene fragments were connected head to tail. Thus nucleotides from position 391 
to 486 were successfully deleted from the gene (Fig. E-9). As for construction of the 2 
site-specific point mutations, bbk32PHei (73-600) mut and bbk32B31 (73-600) mut, 4 amino acids of 
BBK32 from each isolate were mutated by codon replacement. We found two unique 
restriction enzyme sites (BstF51 and HaeⅢ) proximal and distal the region conceiving the 
4 amino acids to be replaced. Thus the regions between the two restriction enzyme sites 
were exchanged between bbk32 gene fragments from PHei and B31 after a series of 
digestion and ligation treatments (Fig. E-11). 
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In summary, the interaction of B. burgdorferi s.l. BBK32 and human Fn is mainly mediated 
by the N-terminal region, and especially the 32-amino acid-long segment of BBK32 by 
binding to the collagen-binding domain of Fn (repeat I6-9 and II1, 2) and partially to its 
N-terminal fibrin binding domain (repeat I1-5). Because of the variation of the 4 amino 
acids (K131, K145, T147 and I155) in BBK32 of isolate PHei, its binding capacity to Fn 
increases greatly compared with BBK32 proteins from isolate B31, and this high affinity to 
Fn is only partially inhibited by gelatin or collagen in comparison to that of its homologue 
from B31. Surprisely, we found BBK32 from B. burgdorferi s.s. B31 should also be a 
collagen/gelatin binding protein. 
3. Application of recombinant BBK32 proteins in serological 
diagnosis of Lyme borreliosis 
Some studies indicated that BBK32 might be a good antigen for detection of specific 
antibodies of patients suffering from Lyme borreliosis (Heikkilä et al., 2002; Lahdenne et 
al., 2003; Panelius et al., 2003; Lahdenne et al., 2006). One investigation also indicated 
that BBK32 fragments might improve the early IgG serology of Lyme borreliosis 
compared to the BBK32 whole protein (Lahdenne et al., 2006). An in-house recombinant 
immunoblot assay for serodiagnosis of Lyme borreliosis was previously established in our 
laboratory (Max von Pettenkofer institute) (Wilske et al., 1999; Schulte-Spechtel et al., 
2003, 2006; Goettner et al., 2005). Therefore, we checked the possibility of improving the 
immunoblot established by our laboratory by addition of some BBK32 proteins as antigens.  
In Europe and Asia, the development of a uniform approach for the serological evaluation 
of Lyme borreliosis is complicated by the prevalence of organisms from the three or more 
genospecies of B. burgdorferi s.l. and by the antigenic diversity due to variations in the 
sequences and expression of immunogenic proteins in these different borrelial species 
(Wang et al., 1999b; Baranton et al., 1992; Robertson et al., 2000; Roessler et al., 1997; 
Goettner et al., 2005; Schulte-Spechtel et al., 2003, 2006). Both former studies (Heikkilä et 
al., 2002) and our results indicated BBK32 proteins were quite heterogeneous (Fig. E-25). 
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We also realised that BBK32 proteins had a much higher heterogenicity at amino acid 
sequence level than at DNA sequence level (Fig. E-26). This may be due to the immune 
selection as Borreliae binding to Fn might evade humoral immunity of its host. In order to 
cover all pathogenic Borrelia species that cause human Lyme borreliosis, we prepared 8 
BBK32 homologues from different strains of the three pathogenic species, B. burgdorferi 
s.sl, B. afzelii, and B. garinii. 
The respective variant BBK32 recombinant proteins were tested for use in Lyme borreliosis 
serology by using serum samples from patients with early- and late-stage Lyme borreliosis. 
Results indicated rBBK32 from B. burgdorferi s.s. and B. garinii could be valuable 
antigens for diagnosis of Lyme borreliosis, especially in ACA. Our results also suggested 
for improvement of sensitivity, that entire BBK32 proteins should be applied rather than 
truncated ones.  
Former studies suggested that epitope specific antibodies might be induced by different 
species of B. burgdorferi s.l. (Heikkilä et al., 2002; Lahdenne et al., 2003). As shown in the 
AA homology tree (Fig. E-26), BBK32 sequences in B. afzelii were quite different from 
those in B. garinii and B. burgdorferi s.s.. We speculated that most of the pathogenic agents 
of those borreliosis patients of our sera sources in this study were likely infected with B. 
garinii or B. burgdorferi s.s.. And this might explain the low percentage reactivity of 
antibodies with BBK32 proteins from strain PKo of B. afzelii. To prove this, pathogenic 
Borreliae should be isolated from patients and ospA PCR should be performed in order to 
differentiate related B. burgdorferi s.l. isolates as described elsewhere (Michel et al., 2003). 
This further implies that in regions where Lyme borreliosis is caused by different species of 
B. burgdorferi s.l., variant BBK32 antigens are probably needed to cover all the EM cases. 
After the first round of purification of recombinant BBK32 proteins with either Ni-NTA 
beads or Glutathione Sepharose 4 Fast Flow beads, resulted to some contaminations from E. 
coli proteins. To get rid of this, a second round of purification with Polyacrylamide gel was 
performed. As demonstrated in this study there were no non-specific reaction bands visible 
after the second round of purification (Fig. E-28). Although with its short-coming of quite 
low efficiency, the method is still reliable in some experimental test where only small 
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amounts of proteins are needed. In the future, some other methods will be tried for 
large-scale purification of proteins. 
However, though BBK32 homologues could react with Lyme borreliosis patient sera, 
compared with other antigens on the in-house immunoblot established in the Max von 
Pettenkofer Institute (Wilske et al., 1999; Schulte-Spechtel et al., 2003, 2006; Goettner et 
al., 2005), these homologues could not improve the method in detection of either IgG or 
IgM antibodies. Nevertheless, the study underlines the fact that the heterogeneity of 
Borrelia strains and species must be taken into consideration in the serological diagnosis of 
Lyme borreliosis in European patients. 
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G. CONCLUSION 
The location of bbk32 gene varies among different Borrelia species and might even differ 
between strains. The gene was not detected by PCR and Southern-blot in some strains, 
which suggest the loss of corresponding plasmids harboring the bbk32 gene in those strains 
during in vitro cultivation. Other reasons might be that bbk32 genes in some strains have 
distinct sequences and are not recognized by the three probes prepared from strains B31, 
PKo and PBi. 
BBK32 from B. garinii strain PHei exhibits a much stronger Fn-binding capability when 
compared to its homologue from B. burgdorferi s.s. strain B31. The 32 amino acids (from 
position 131 to 162) in the N-terminal region are mainly responsible for the Fn-binding 
capability of the protein. The substitution of the 4 amino acids (K 131 Q, K 145 E, T 147 P 
and I 155 L) in the Fn-binding region of BBK32(PHei) is abrogated the higher affinity of 
BBK32PHei to Fn. The interaction of BBK32 and human Fn is mainly mediated by the 
N-terminal region, and especially the 32-amino acid-long segment of BBK32 by binding to 
the collagen-binding domain of Fn (repeat I6-9 and II1, 2) and partially to its N-terminal 
fibrin binding domain (repeat I1-5).  
Though BBK32 homologues react with serum antibodies from some Lyme borreliosis 
patients, these homologues could not improve the serological test in detection of either IgG 
or IgM antibodies. Nevertheless, the study underlines the fact that the heterogeneity of 
Lyme disease Borrelia species must be taken into consideration in the microbiological 
diagnosis of Lyme borreliosis in European patients. 
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I. LIST OF ABREVIATIONS 
ACA acrodermatitis chronica atrophicans 
APS Ammonium persulphate 
bp Base pairs 
BSA Bovine Serum Albumine 
BSK-II medium Barbour-Stonner-Kelly-II medium 
CDC Center for disease control 
CSF Cerebrospinal fluid 
DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
EDTA Ethylendiamintetraacetic acid 
EM erythema migrans 
EtBr ethidium bromide 
Fig. Figure 
Fn fibronectin 
FnBP Fn-binding protein 
g gram 
GBD gelatin-binding domain 
h hour 
HRP Horseradish peroxidase 
IPTG Isopropyl-β-thiogalaktopyranosid 
kb kilobase 
kDa kilodalton 
l liter 
LB broth Luria Bertani broth 
M molar 
MCS multiple cloning site 
Min minute 
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MKP-medium Modified Kelly-Pettenkofer medium 
ml milliliter 
mM milimolar 
MW Molecular weight 
µl microliter 
NB neuroborreliosis 
NC Nitrocellulose 
NCBI National Center for Biotechnology Information 
NTD N-terminal domain 
OD Optical density 
o/n overnight 
ORF open reading frame 
Osp outer surface protein 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFGE Pulsed Field Gel Electrophoresis 
pH power of hydrogen 
PMSF phenylmethylsulphonyl fluoride 
rpm revolutions per minute 
RT Room temperature 
Sec second 
SfbI Streptococcal fibronectin binding protein I 
SD standard deviation 
SDS Sodium dodecyl sulphate 
TEMED N,N,N’,N’-Tetramethylendiamine 
Tris Tris-hydroxymethyl-aminomethane 
Tween 20 Polyoxyethylensorbitanmonolaureate 
v/v volume/volume 
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w/v weight/volume 
X-Gal 5-Bromo-4-Chloro-3-Indolyl-β-D-Galaktosid 
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J. APPENDIX 
Nucleotide sequences of the cloned gene fragments and constructed mutations of bbk32. A. 
gene fragments of isolate B31, and B. gene fragments of isolate PHei. 
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